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Basal transcription
The blueprint for life is encoded in the DNA (deoxyribonucleic acid) of all animals. 
DNA is a polymer strain of four different bases of two different types; the purines 
adenosine (A) and guanine (G) and the pyrimidines thymine (T) and cytosine (C). 
Every cell in our body, except germline cells, immune cells and erythrocytes, has the 
same set of DNA. The DNA contains genes that can be transcribed to messenger 
ribonucleic acid (mRNA) which serves as the template to be translated to protein. 
Proteins (and RNAs) carry out the biochemical processes in the cell like metabolism, 
signal transduction and DNA transcription. DNA in the mammalian cell is about two 
meter long and has to be compressed in a small nucleus that is about 5 micrometre 
wide. In order to fit all the DNA into this tiny space it is wrapped around proteins 
called histones. Around 200 base-pairs are wrapped around eight histones which 
are organised in a structure called a nucleosome creating a “beads on a string” 
conformation. Although the wrapping of DNA around nucleosomes condenses the 
DNA about seven times this is not sufficient to explain the compact structure of the 
genome. Multiple nucleosomes create chromatin that further compacts the DNA and 
forms the chromatid.
Chromatin can be in a closed or an open conformation and switch between 
these conformations. This is called chromatin remodelling. Genes in the closed 
conformation (called heterochromatin) are not transcribed, and genes that are active 
are in open conformation (called euchromatin). Heterochromatin is also associated 
with gene poor regions like telomeres. Also is the DNA of heterochromatin often 
methylated and are the histone modifications different than euchromatin.
The specific function of a cell is determined by set of genes that are transcribed; a 
large number of these are expressed in all cells to carry out general functions and a 
much smaller number that are cell type specific and code for the specific function of 
the cell. There are over 25000 genes in the mammalian genome and they are either 
transcribed or repressed. 
The transcription of DNA to RNA is facilitated by RNA polymerases. Mammals have 
three types called RNApol I, II and III. RNApol II is responsible for the transcription of 
almost all protein coding genes. RNApol I and III transcribe ribosomal RNA and small 
nuclear RNA. RNA pol II is part of a large protein complex called TFII (transcription 
factor for RNA pol II) which consists of several subunits indicated from A to H. These 
transcription factors are called “general” transcription factors because they are 
important for the transcription of almost all protein coding genes. A large part of the 
TFII transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH) are part of 
the transcription initiation complex that positions RNA pol II over the transcription 
start site (TSS). TFIIA binds to TFIID and aids this domain in binding to the TATA 
box present in many promoters. TFIIB serves as a bridge between TFIID and RNA 
pol II. Later TFIIE comes in to the complex and recruits TFIIH that is a DNA helicase 
and breaks the hydrogen bonds between the two DNA strands. TFIIH also catalyzes 
phosphorylation of the RNA pol II C-terminal tail that is needed for transcription 
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elongation. TFIIF is needed to stabilise the binding of RNA pol II to the whole 
complex. When the transcription initiation complex together with RNA pol II is loaded 
at the TSS the DNA present is partly melted and this is called transcription initiation. 
After this first initiation the gene can be re-initiated without the whole complex to be 
assembled again[1]. When initiation has taken place the RNA pol II will move along 
the DNA in a process called elongation. Elongation consists of two steps with the first 
step phosphorylated RNA pol II that moves along the DNA strand and gets a stable 
grip. Then this movement is paused until RNA pol II is hyperphosphorylated and 
Figure 1: Folding of DNA in eukaryotic cell. 
The double helix of DNA is wrapped around histones and form nucleosomes. Nucleosomes form 
chromatin and is condensed further in the nucleus forming chromosomes. Adapted from Gary Felsenfeld 
and Mark Groudine
DNA double helix
Nucleosomes
“beads-on-a-string”
Chromatin
Section of chromosome 
in extended form
Condensed section of chromosome
Meitotic chromosome
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elongation continues through the whole gene[2]. When a gene is fully transcribed 
RNA pol II disassociates from the DNA and the transcription is terminated. RNA 
synthesis by RNA pol I and III is terminated by recognition of a specific sequence 
called the terminator. The process of termination is poorly understood in RNA pol 
II transcription, but recent studies show a link to the initiation complex via TFIIB[3]. 
Another poorly understood process in transcription by RNA pol II is stalling. In this 
process RNA pol II stalls after having transcribed a fragment of the RNA and then 
falls of the DNA. The reason why stalling exists in the eukaryotic cell is unclear 
but research suggests that it is partly a mechanism for regulating transcription of 
developmental genes[4-5].
It is thought that this general TFII complex is recruited to genes by tissue specific 
and non-specific transcription factors. The basal transcription process alone is not 
sufficient for the process of transcription in vivo, but is dependent on other proteins 
called transcription factors (TF). TFs can bind promoters of genes that are located 
upstream of a gene and can be of variable size. Promoters are DNA elements of 
approximately 200 bp directly upstream of the transcription initiation site but 
can also extend into the gene. TFs can also bind enhancers/silencers and locus 
control regions; these are DNA elements that can act over very large distances, 
sometimes even more that 1Mb[6-8], on the transcription of genes. It is thought 
that these elements interact with the transcriptional start site via DNA looping and 
bring in factors to the transcriptional start transcription. These factors can influence 
transcription by e.g. modifying histones or start elongation. 
TFIIA
TFIID TFIIB
RNA pol II
TFIIE
TFIIH
TFIIF TFIIA
TFIIDTFIIB
RNA pol II
TFIIE
TFIIH
TFIIF
Figure 2: Complex forming RNA pol II initiation complex. 
See text for explanation.
Development and differentiation
Animal life starts out with one omnipotent cell that is created by fertilization of an 
egg cell. For this cell to develop into an organism this single cell needs to proliferate 
to create more cells and these new cells need to differentiate into specialised cells 
and migrate to the proper location in the embryo. For a cell to differentiate from an 
embryonic stem (ES) cell to a specific tissue several intermediate cell stages are 
necessary. During this development the TF programmes change to proceed in the 
differentiation. An example is the TF Oct-4 that is expressed in ES cells and binds 
to the DNA sequence ATGCAAAT. Loss or altering the expression levels of Oct-4 in 
stem cells results is a loss of pluripotency and triggers differentiation[9-11]. When the 
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ES-cell for example starts to differentiate into the haematopoietic direction the TFs 
SCL and Gata2 start to be expressed. These TF are important for the generation of 
the definitive haematopoietic stem cell (HSC)[12-13]. The TF Gata2 is repressed 
when the HSC differentiates into the direction of erythrocytes and simultaneously 
Gata1 starts to express (reviewed in [14]). 
The cell “knows” which transcription factors are necessary by activation of there 
genes by other transcription factors and extracellular signalling. An important group 
of proteins that regulate the specific pattern of gene expression in different cell types 
are the “tissue specific” TFs. These TFs bind directly or indirectly to the DNA and 
activate or repress transcription of specific genes. 
Histone modifications
The nucleosome consists of five types of histones called H1, H2A, H2B, H3 en 
H4[15-16]. Histones can be modified at there N-terminal tails by various biochemical 
modifications like acetylation, methylation, phosphorylation, ubiquitination and 
sumolation (reviewed in[17]). In addition to these modifications also specialized 
histones exist like H2AZ and H2AX. These histones have a variation in there 
sequences and for example have a role in DNA repair and transcription[18]. 
Modifications of histones can be of a repressive or activative nature. The most 
frequent modifications are acetylation and methylation. Acetylation of lysine residues 
in the histone N-terminal tails is performed by Histone Acetyl Transferases (HAT) and 
is largely associated with active chromatin and mostly located at the transcriptional 
startsite of a gene[19-21]. The acetylation of histones is reversible and is removed 
by Histone Deacetylases (HDACs). Acetylation marks on the histone tails are 
recognised by proteins with a bromodomain. This domain is present in a wide range 
of transcription factors such as acetyltransferases (e.g. p300), chromatin remodelling 
proteins (e.g.SWI/SNF) and general transcription factors (e.g.TAFII250)[22-23].
The methylation of histones is more complex because the lysine residues in the tails 
can be mono, di or tri-methylated. All but one of the known histone methyltransferases 
(HMT) contain a SET domain that catalyzes the methylation activity. Histone 
methylation is associated with both gene activation and repression. Enhancers, the 
promoter and the body of a gene are methylated in a specific way contributing to 
the regulation of transcription[24]. Lysine methylation marks are recognised by the 
chromodomain that is associated with chromatin remodelling proteins[25].
Recently a histone demethylase was discovered called Lysine Specific 
demethylase1 (LSD1)[26]. It was shown that this enzyme removes histone 3 
lysine 4 (H3K4) mono- and di- methyl marks and possibly also histone 3 lysine 9 
(H3K9) mono- and di- methylation[27]. H3K4 methylation is associated with active 
genes and this suggests that LSD1 functions as a repressor[24, 28]. H3K9 di- and 
tri-methylation is associated with repressed genes thus LSD1 could possibly also 
have an activation role, although H3K9 mono-methylation is associated with active 
genes[29-31]. Other histone demethylases were discovered later e.g. LSD2 and 
some members of the Jumonji family of proteins[32-33], which have been shown to 
demethylate lysine trimethyl marks[34]. LSD1 has been shown to be important for 
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definitive erythroid development in mouse. It forms complexes in erythroid cells with 
important erythroid transcription factors like Gfi1b, TAL1 and Gata1[35-37]. Hence 
the methylation status of several erythropoietic genes has been suggested to be 
regulated by LSD1 but a specific role or function has not been assigned to LSD1 in 
erythropoiesis yet[37-38]. This is particularly relevant in the context of this thesis on 
definitive erythropoiesis. 
Arginine residues in proteins can also be methylated by a different family of 
methyl transferases, the Protein Arginine Methyl Transferases (PRMT). This type 
of methylation is different from lysine methylation. Arginine methylation can occur 
in three fashions: 1) in a symmetrical dimethylated fashion with one methyl group 
placed on each of the terminal nitrogen atoms. 2) In an asymmetrical dimethylated 
fashion with two methyl groups placed on one of the two terminal nitrogen atoms. 3) 
In a monomethylated fashion with one of the terminal nitrogen atoms methylated. 
The arginine methylation has also been linked to histones and their modification. 
For example the histone 3 tail is methylated on a number of different arginine 
residues[39-40] and an arginine histone demethylase has been reported[41].
Chromatin remodelling complexes
The eukaryotic DNA is composed of chromatin that in turn makes the DNA compact. 
This creates a problem for transcription, DNA repair and replication. Nucleosomes 
need to be relocated or removed from the DNA to expose TF binding sites or start 
repair/replication process. For the chromatin to be remodelled between open and 
Figure 3: Representation of DNA looping of enhancer to promoter of an RNA 
pol II transcribed gene. Adapted from book: The cell; a molecular approach.
Initiation complex
Enhancer/silencer, Locus Control Region
DNA loop
Transcription factors
Promoter
Book: The cell; a molecular approach
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closed conformation the cell uses chromatin remodelling complexes. Examples of 
these complexes in mouse are the BAF complex (SWI/SNF in yeast), INO80, NURD 
and ISWI, which are important for execution of a number of different developmental 
programs(reviewed in [42]). These complexes utilise ATP to remodel chromatin and 
do this with a specific subunit like BRG1 for BAF and SNF2L for ISWI. All these 
complexes bind nucleosomes and have domain that bind specific transcription 
factors, e.g. Oct-4 or epigenetic marks[43]. Every chromatin remodelling complex 
contains Actin Related Proteins (ARP) that are homologues to Actin, a spatial 
organizer in cells, and are thought to be needed to create 3D DNA structures. 
Mutations in these subunits result in a wide range of phenotypes[44-46]
Haematopoiesis
The production of all haematopoietic cells such as T-cells, B-cells megakaryocytes 
and erythrocytes is called haematopoiesis. All these cell types are derived from a 
common stem cell called the haematopoietic stem cell (HSC). The HSC is believed 
to be derived from a common mesodermal precursor for endothelial cells and 
haematopoietic cells called the hemangioblast. These hemangioblast cells express 
the mesodermal markers Brachyury and Fetal Liver Kinase 1 (FLK1)[47-48]. The 
hemangioblast gives rise to hemogenic endothelium regulated in part by SCL/
TAL1[48-49]. In mammals there are two waves of haematopoiesis derived from 
this endothelium called the primitive haematopoiesis regulated in part by the Wnt 
signalling pathway, and the definitive haematopoiesis regulated in part by the Notch 
signalling pathway. These processes include a number of TFs some of which are 
essential for one stage, e.g. Runx1 is essential for definitive haematopoiesis[50-52]. 
The haematopoietic system is widely used as a model system for cellular and 
molecular mechanisms of differentiation and has provided many basic insights into 
gene regulatory processes that also apply to other cell systems. In addition it is an 
important system to study in the context of disease, such as leukaemias, anaemias 
and the hemoglobinopathies and provide the molecular basis for the development of 
novel therapies to treat these disorders.
Primitive Haematopoiesis
Primitive haematopoiesis or primitive erythropoiesis occurs in the yolk sac in blood 
islands at day 7.5 days post coitum (dpc) from hemangioblast cells that migrated 
there from the primitive streak[53-54]. These primitive HSC do not persist through 
the development of the embryo and are absent in the adult mouse. The primitive 
HSC’s do not have the ability to selfrenew and colonize bone marrow. They give rise 
to primitive erythrocytes and disappear around day 9dpc, but primitive erythrocytes 
persist longer in the bloodstream[55]. They co-exist for a short while with erythrocytes 
from definitive HSC that will replace them fully later in development. Primitive 
erythrocytes are larger than there definitive counterparts and express the embryonic 
globin genes ζ, εy and βh1[56-57].
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Definitive haematopoiesis
Transplantation studies have shown that there are multiple sites of definitive 
HSC generation. The first site is the para-aortic-splanchnopleura that’s develops 
in the aorta-gonad-mesonephros (AGM) region. Definitive HSC derive on the 
ventral side of the dorsal aorta where they are generated de novo at day 10dpc 
from the endothelium as clusters[58]. Definitive HSCs can differentiate into every 
haematopoietic linage, they keep this potential throughout adult life and have 
the capacity to self-renew. The suggestion was made that there are secondary 
sites of definitive HSC generation based on the quantification of the number 
of HSCs generated in the AGM region and studies done with Runx1 and GATA1 
haploinsufficient mice[59-61]. This resulted in the discovery that the mouse and 
human placenta also are a site of HSC generation or amplification[62-64]. The yolk 
sac has also been mentioned as a potential site for definitive HSC generation[65], 
however the evidence to support this flawed because when these cells were injected 
directly into adult mice they were incapable of engraftment.
Several TFs have been shown to be essential for the development of HSC including 
the Gata transcription factor family and the Core Binding Factor family, which are 
the focus of the work described in this thesis.
Erythropoiesis
Erythropoiesis is the generation of red blood cells or erythrocytes via several 
different cell stages from the HSC. They transport of oxygen throughout the body 
and contain haemoglobin, the protein that binds oxygen in the lungs and releases 
it in the tissues. Erythrocytes have a lifespan of 120 days in humans and make 
up about 45% of the blood volume. They are generated in large numbers during 
the primitive and definitive stages of erythropoiesis and are often described as 
EryP (P for primitive) and EryD (D for definitive). The differentiation to the mature 
erythrocyte starts with the self renewing HSC which gives rise to a multipotent 
progenitor (MPP). This cell is thought to have lost the ability to selfrenew but retain 
the same differentiation potential. In the direction of erythroid development this cell 
develops into the common myeloid progenitor (CMP) splitting of from the common 
lymphoid progenitor (CLP) that gives rise to B- and T-cells. The CMP gives rise to 
the megakaryocyte-erythroid progenitor (MEP), splitting off from all other myeloid 
cell lineages. The MEP is committed to either the megakaryocyte lineage or the 
erythrocyte linage. The next cell type in erythrocyte differentiation is the burst 
forming units-erythroid cell (BFU-E) followed by the colony forming unit-erythroid 
(CFU-E). With the differentiation into the proerythroblast “terminal erythroid 
differentiation” is initiated, i.e, the immature precursors become erythrocytes. From 
the proerythroblast the basophilic erythroblast is formed and then the polychromatic 
erythroblast. The next stage is the orthochromatic erythroblast that enucleates 
forming the reticulocyte. The shape of the cell changes into a biconcave and the 
mature erythrocyte is formed.
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Figure 4: Definitive mouse haematopoiesis. 
LT-HSC (long term haematopoietic stem cell), ST-HSC (short term haematopoietic stem cell), MPP 
(multipotent progenitor), CMP (common myeloid progenitor), MEP (megakaryocyte erythrocyte 
progenitor), GMP (granulocyte macrophage progenitor), CLP (common lymphoid progenitor). Adapted 
from Robert Margolin and Yusra Abidi
Examples of transcription factors known to be involved in erythropoiesis are Gata1, 
EKLF or KLF1, LDB1, LMO2, LMO4, p45/NF-E2 and TAL1/SCL [13, 66-71]. Gata1, 
TAL1/SCL and EKLF have been shown to be important in primitive and definitive 
erythropoiesis[70, 72-73]. Next to these essential transcription factors there are 
a number co-regulators essential for erythropoiesis. For example FOG1 which 
binds to the Gata proteins help to recruit important transcriptional complexes[74]. 
Similarly p300 a HAT which binds Gata1, TAL1/SCL and EKLF has been implicated 
in haematopoietic development[75-78] and BRG1 which is part of the BAF complex 
has been shown to bind to important erythroid genes. BRG1 hypomorphic mice also 
have a block in erythroid development [76-77, 79]. 
Robert Margolin and Yusra Abidi
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Transcription factors involved in haematopoiesis
The generation of HSC and the process of differentiation to all the blood cells in 
the body is dependent on a large number of transcription factors and the process 
of unravelling the regulatory network of TFs involved in haematopoiesis is still in 
an early stage. With new technologies like very sensitive mass spectrometry and 
”next generation” sequencing this process is speeding up rapidly to enhance our 
understanding of haematopoiesis. 
Here I will focus on a small number of factors, namely SCL/Tal1, Gata2 and Runx1 
known to be essential for the emergence of the early haematopoietic cells and 
Gata1, Pu.1 and GFI1b known to be essential for the differentiation towards myeloid/
erythroid blood cells.
Core binding factors
The core binding factors were first discovered as proteins binding to the core 
sequence of the Moloney virus enhancer[80]. The mammalian Core Binding Factor 
(CBF) family consists of the α subunits Runx1, 2 and 3 and their common partner 
the β subunit CBFβ. The α subunits are DNA binding proteins via there Runt domain 
to the consensus [TC]G[TC]GGT[TC][81-82]. This binding to the DNA is enhanced 
by binding of CBFβ[83]. The Runt domain is homologous to the drosophila runt 
gene involved in segmentation. Other names for the core binding factor family are 
papyloma enhancer binding protein (PEBP)[84] and AML due to the discovery that 
Runx1 is often a target for translocation in acute myeloid leukemia (AML). The CBF 
family is conserved in many animal species from human to sea urchin. Drosophila 
has four α subunit genes called runt, lozenge, CG34145 and CG42267, and two 
β subunit genes called brother and big brother. C.elegans contains one α subunit 
called rnt-1 and one β subunit called bro-1. Human and mouse have three α subunits 
called RUNX1, RUNX2 and RUNX3 and one β subunit called CBFβ.
The CBFs were discovered as frequent targets of chromosomal translocations in 
leukaemias[85-86]. Examples of core binding factor translocations fusion proteins 
Figure 5: Definitive mouse erythropoiesis. 
Differentiation of erythrocytes from the HSC (haematopoietic stem cells) via the CMP (common myeloid 
progenitor) to the proerythroblast. On top examples of transcription factors important in erythropoiesis. 
Ldb1
Gata2, KLF1
Tal1, Lmo2
Ldb1
Gata1, KLF1
Tal1, Lmo2
Ldb1
Gata1, KLF1
Tal1, Lmo2, E2ALmo4
HSC CMP Proerythroblast Erythrocyte
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are CBFβ-SMMHC, AML1-EVI1, TAL1-AML1 and AML1-MTG16. The most 
frequently occurring translocation is the t8:21 that generates the chimaeric protein 
AML1-ETO. This is a fusion of almost the entire ETO protein with the DNA binding 
domain of Runx1 and creates a protein that binds to Runx1 target genes but can 
only repress these genes[87]. In human acute myeloid leukaemias (AML) this 
translocation is present in 10% of all cases. Runx1 and CBFβ are often targets of 
translocations in AML[88-90].
Patients with an AML1-ETO translocation often show a hypoplasia, a disruption of 
the erythroid and megakaryocytic differentiation[91]. This observation was also seen 
in mouse models expressing AML1-ETO fusion protein[92]. Contradictory to these 
results is that a different AML-ETO mouse model does not show the hypoplasia 
phenotype[93]. A zebrafish model with inducible expression of AML1-ETO showed 
a downregulation of Gata1 and SCL, two factors important for haematopoiesis and 
erythropoiesis[94]. In in vitro cell cultures of erythroid cell lines it has also been 
shown that AML1-ETO inhibits the differentiation of K562 cells, MEL cells and human 
primary erythroid cells[95-97].
A knock-out (KO) model of Runx2 resulted in a bone formation phenotype and Runx2 
was shown to be essential for the maturation of osteoblasts[98-99]. It also targets 
the Indian Hedgehog pathway that is important for chondrocyte development[100]. 
Runx2 has not been linked to human cancers like its family member Runx1. Runx3 
is expressed in many cell types e.g. epithelial cells, blood cells and neural cells. 
A knock-out (KO) model of Runx3 gave a wide variety of phenotypes[101]. The 
most dominant phenotype was seen in the gastric system. Runx3 was later shown 
to function as a tumour suppressor in gastric mucosa. It is also involved in T-cell 
development[102-103]. This thesis will focus on Runx1 and its function. 
Runt related factor 1
Runx1 was first cloned as a t(8;21) translocation that occurs frequently in Acute 
Myeloid Leukemia (AML)[85, 104]. In addition to the runt domain Runx1 also contains 
a transactivation domain and multiple repressive domains. It can therefore act as an 
activator and a repressor. Runx1 and CBFβ have been shown to be important for 
haematopoiesis in several studies. Runx1 deficient mice do not develop definitive 
HSC and closer inspection showed a complete absence of haematopoietic clusters 
in the AGM region[105-106]. The embryos die between 12.5dpc and 13.5dpc and 
have haemorrhages in the central nervous system. The CBFβ knock-out mouse 
shows a similar phenotype as the Runx1 knock-out mouse which illustrates that 
the complex of these two TFs is important for proper gene regulation[107-108]. 
Nevertheless some definitive haematopoietic progenitors were found in the fetal 
liver, but these appear to be defective as they are not capable of engrafting irradiated 
mice by transplantation. 
People suffering from Down syndrome have trisomy 21. The runx1 gene in humans 
is located of chromosome 21 and they can have an overexpression of Runx1. These 
people have a 50% higher incidence of leukaemias and a possible role in this could 
be linked to the runx1 gene[109]. Also the generation of the hemogenic endothelium 
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is affected in trisomy 21 ES cells[110]. 
After the emergence of the HSC Runx1 is important for megakaryocytic, B-cell and 
T-cell development. Upon Runx1 deletion in adult mice a megakaryocytic phenotype 
was seen[111]. The maturation of megakaryocytes was arrested and this phenotype 
was also seen in adult mice that were CBFβ hypermorphic[112]. In several other 
studies it has been shown that Runx1 has a role in the development of T-cells and 
B-cells of the adult mouse[113-114]. 
Runx1 post-translational modifications
Like histone proteins Runx1 can also be modified by phosphorylation, methylation 
and acetylation. These modifications can have an important role in the regulation of 
Runx1 function in the cell. 
Phosphorylation of Runx1 occurs on serine and threonine residues which changes 
its biochemical properties. Phosphorylation of serine 246 and 266 by ERK disrupts 
the binding of Runx1 with the repressor protein mSIN3a[115]. Arginine methylation 
by PRMT1 at positions 206 and 210 also disrupts the binding of Runx1 with 
mSIN3a[116]. This methylation is tissue specific and occurs for example in the 
erythroid linage but not in the megakaryocytic lineage[117]. Acytelation of lysine 
residues 24 and 43 by p300 increases the ability of Runx1 to bind DNA[118].
Runx1 gene locus
All the three runx genes contain two promoters, a proximal and distal promoter[119-
120]. The proximal promoter resides in the first intron of the genes. The runx1 first 
intron is about 130kb and contains at least one enhancer needed for proper Runx1 
expression[121-122]. There are many conserved sites in the first intron, which 
are thought to be regulatory regions but the intron probably contains even more 
regulatory sites[49, 122]. During development the proximal promoter of the runx1 
gene is mainly used during the onset of haematopoietic development. Transcription 
via the distal promoter increases during embryo development and is almost the 
only promoter transcribed in the adult mouse[123]. The runx1 gene in the mouse 
embryo is activated by Notch, SCL/TAL1, LMO2 and LDB1[49, 52, 124-126][Mylona 
et al unpublished]. Later in development the expression is regulated by Runx1 itself, 
Gata1 and SCL/TAL1[122-126]
Runx1 binding partners
Runx1 binds both co-repressors and co-activators. Therefore it can act as a 
transcriptional repressor or activator. The role of Runx1 in the development and 
differentiation of the haematopoietic system can be split into two: one for the 
emergence of the HSC for which Runx1 is absolutely essential and one after the 
emergence of the HSC. Mouse knock-in studies where the repressor fusion protein 
AML1-ETO replaces Runx1 show that Runx1 mostly acts as an activator in the 
development of definitive HSC. After the HSC emerge its function seem to switch to 
Introduction
22
being a repressor [93, 127-128]. How Runx1 alters its transcriptional role depends 
on the protein partners that cooperate with Runx1 in the different tissues.
Lim Domain Binding protein 1
Lim Domain Binding protein 1 (LDB1) is a homologue of the Drosophila CHIP 
protein that is thought to be involved in long range DNA-DNA interactions[129]. 
The mouse LDB1 knock-out model dies at 10.5dpc and displays a haematopoietic 
phenotype[130]. In the erythroid development LDB1 is suggested to be important 
for proper β-globin expression by organising the 3D chromatin structure of the 
locus[131-132]. Runx1 was found in a screen to identify protein partners of LDB1 in 
Mouse Erythroid Leukemic (MEL) cells [66], but its role in erythropoiesis is largely 
unknown. LDB1 binds DNA via GATA1 and TAL1 and mostly binds genes that are 
activated in the last steps of erythroid differentiation[133].
Groucho/TLE
All the Runx proteins contain a VWRPY amino acid sequence at the C-terminus. This 
domain recruits the repressor TLE, homologue of the Drosophila Groucho, to the 
Runx1 protein[134]. Deletion of this domain in mouse gives a T-cell phenotype[135-
136]. Runx1 binds to the cd4 silencer[103] in agreement with the observation that 
more CD4 positive T-cells are observed when Runx1 lacks the VWRPY domain. 
Runx3 also has a role in T-cell development, it regulates the cd4 and cd8 genes and 
binds to the cd8 enhancer in mature T-cells[102, 137]. However it is unclear whether 
the VWRPY domain is obligatory for this function.
The TGFβ pathway
The TGFβ signalling pathway comprises a family of extracellular molecules (TGFβ) 
and receptors that regulate together with the Bone Morphogenetic proteins (BMP) 
the SMAD family of TFs. The Runx proteins have been shown to interact with 
some SMAD factors[138] and similar roles of the TGFβ pathway and Runx proteins 
Figure 6: Schematic representation of the structure of the Runx1 gene locus. 
Promoters, transcription start sites (ATG) and exons (black blocks) shown. Runx1 gene locus contains 
two promotors. P1 or distal promoter and P2 or proximal promoter. Exons 3,4 and 5 encode runt domain 
of Runx1 protein.
Distal promoter
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have been observed in bone formation and induction of IgA. These functions are 
performed by Runx2 and Runx3 respectively [138-140]. However even tough all 
Runx proteins bind to SMAD’s no functional overlap has been found for TGFβ and 
Runx1.
The GATA transcription factor family
The GATA transcription factor family is essential for development of different tissues. 
The family consists of six members that are expressed in different tissues at different 
time points (reviewed in [141]) The proteins are zinc-finger proteins that bind DNA 
directly via the sequence (A/T)GATA(A/G) that also gave them their name.
Gata1 was the first of the family to be discovered as an specific binder to the beta-
globin 3’ enhancer[142]. Later Gata1 was shown to be essential for erythrocyte 
development but is also expressed in dendritic cells, megakaryocyte and eosinophil 
cell lineages[143-144]. Gata1 null erythrocytes arrest in the proerythroblast stage 
and fail to develop in mature erythrocytes. Runx1 has been shown to be a partner of 
Gata1 via direct binding in megakaryocytes and both Runx1 and Gata1 loss in adult 
mice results in a megakaryocytic phenotype[111, 114, 145-147]. Runx and Gata have 
also been linked to each other in transcriptional control in other cell types[148-149]. 
To date (excluding the study presented in this thesis) only the cd41 gene has been 
linked to being regulated by both Gata1 and Runx1[112, 150-151]. In Drosophila the 
Runx1 and Gata1 orthologues, respectively lozenge and serpent, have also been 
shown to cooperate in the development of the haematopoietic system[152-153].
Figure 7: Schematic representation of Runx1 protein. The Runx1 protein is post 
translational modified on shown sites. Known protein partner binding sites show.
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Cell cycle
Runx1 has also been linked to controlling the cell cycle. The first evidence for this 
was the observation that the fusion proteins CBFβ-SMMC and AML1-ETO slow down 
cell cycle progression in the G1 to S progression[154-155]. In several experimental 
systems it was shown that Runx1 stimulates progression of G1 to S phase[155-
157]. These features seemed to be related to the observation that the cell cycle 
genes p21, cdk4 and cyclinD3 are target genes of Runx1[155, 158-159]. The level 
of Runx1 protein is regulated during the cell cycle via phosphorylation of serine 276 
and 303 by CDK’s and this mark is recognised by the Anaphase-Promoting Complex 
leading to the degradation of Runx1[160].
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Aim of the project
Runx1 is known to be essential in the formation of the definitive haematopoietic stem 
cell, but it is not required for its maintenance[161]. Several studies have shown that 
Runx1 plays a role in the differentiation of B-cells, T-cells and megakaryocytes[111, 
113-114]. Erythrocytes are generated together with megakaryocytes from the MEP 
and it is thought that Runx1 is a molecular switch between these two cell types 
(reviewed in [162]). This theory is supported by Runx1 conditional KO mice which 
have a more severe megakaryocytic phenotype in comparison to their erythroid 
phenotype. In addition the Runx1 protein levels drop when the MEP starts to 
differentiate towards the erythroid lineage[145, 163]. Evidence against this theory 
is the result that mice expressing the AML1-ETO fusion protein have a severe 
erythroid phenotype[92]. This is also seen in human suffering from acute myeloid 
leukaemia (AML) with this translocation[91]. In our lab Runx1 was identified to be 
part of a protein complex important for erythropoiesis called the LDB1 complex[66]. 
This complex contains proteins important for erythropoiesis like Gata1, LDB1, Tal1, 
ETO2 and CDK9.
This thesis describes a biochemical approach to understand the function of Runx1 in 
erythropoiesis. Chapter 2 describes how N-terminally tagged Runx1 cDNA with a Bio-
V5-double tag is stably expressed in Mouse Erythroid Leukemic (MEL) cells.  MEL 
cells represent the proerythroblast stage of erythroid differentiation and they can be 
induced to differentiate towards erythrocytes. Immunoprecipitations were performed 
and Runx1 protein partners were identified using mass spectrometry. This showed a 
number of protein partners that were known to be part of the LDB1 complex, but also 
two new partners LSD1 and Myef2. The new partner Myef2 mainly binds to Runx1 
in the proerythroblast stage while LSD1 binds mostly in differentiating cells. The 
analysis of Runx1 genome wide binding shows that Runx1 binds erythroid specific 
genes in both non-differentiated and differentiated MEL cells. This chapter also 
shows that the genome wide binding pattern does not change dramatically during 
differentiation. By decreasing the expression of Runx1 in MEL cells using shRNA it 
was found that Runx1 functions as an activator and a repressor in MEL cells but that 
its function is diminished when MEL cell differentiate. 
Myef2 was not known to have a role in erythropoiesis or haematopoiesis, but Chapter 
2 describes that Myef2 represses important erythroid genes. The role of Myef2 in 
haematopoiesis is further confirmed using knock-down experiments in zebrafish 
(Chapter 3). Repression of erythroid genes by Myef2 is likely mediated via Runx1 
in the proerythroblast stage (Chapter 2). During erythroid differentiation Runx1 
regulates a significant smaller number of genes and in Chapter 4 evidence is shown 
that repression of part of these genes is likely to be mediated by LSD1. Enhanced 
binding of LSD1 to the DNA at Runx1 binding sites is observed after differentiation. 
This enhanced binding correlates with changes in the histone methylation of Runx1 
repressed genes. 
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Abstract
It is known that Runx1 is an essential regulator to generate haematopoietic stem cells, 
but much less is known about its role in the downstream process of haematopoietic 
differentiation. In erythroid cells Runx1 was shown to be part of a large transcription 
factor complex together with LDB1, Gata1, Tal1 and Eto2[1]. By tagging Runx1 in 
erythroid cells we show here that Runx1 binds two repressor proteins LSD1 and 
Myef2. ChIP/seq analysis and microarray expression analysis were used to show 
that Runx1 binds approximately 18 thousand targets in erythroid cells. Functional 
analysis shows that Runx1 regulates these genes in part with the newly identified 
partner Myef2.
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Introduction
The transcription factor Runx1 (AML1, CBFα2) is known to be important for the 
development of the haematopoietic system in mammals. It is part of a small family 
of core binding transcription factors that also consists of Runx2 (AML3, CBFα1) 
and Runx3 (AML2, CBFα3) and CBFβ. Runx1 was first discovered as a homologue 
of the Drosophila segmentation gene runt together with Runx2 and Runx3. The 
Runx1 protein binds directly to DNA via the consensus [TC]G[TC]GGT[TC] [2-
3] and several studies have shown that Runx1 is important for the emergence of 
the haematopoietic stem cell (HSC). The Runx1 knock-out (KO) mouse does not 
develop the definitive haematopoietic system, and has minor defects in the primitive 
haematopoietic system[4-6]. The Runx proteins form a heterodimer with CBFβ 
that enhances the binding to DNA. This dimerization is important for the function 
of Runx1, which is confirmed by the CBFβ KO mouse also lacking definitive 
hematopoietic development[7-8]. 
How Runx1 functions after the emergence of the definitive HSC, and in particular in 
the erythroid compartment, is not well understood, although a conditional knock-out 
shows some defects in the differentiation of erythrocytes. In one model erythrocytes 
show a significantly higher number of Howell-Jolly bodies probably due to the 
hyposplenia. Another model showed an increase in the ratio of maturing myeloid 
to erythroid cells when compared to the controls[9-10]. A recent study has shown 
that Runx1 is also important in primitive erythropoiesis[11]. Defects were found in 
the morphology and Ter119 expression of the primitive erythrocytes. Finally the 
Runx1 homologues are also required for definitive erythropoiesis in non-mammalian 
vertebrates[12-13]. However none of these studies sheds much light on the 
molecular function of Runx1.
From studies using transgenic mice replacing the endogenous runx1 gene in adults 
by a conditional Runx1-ETO fusion gene, a less severe phenotype was observed 
when compared to the mouse adult conditional knock-out of Runx1[9-10, 14]. The 
AML1-ETO fusion gene is a fusion of the Runx1 binding domain to almost the 
entire eto gene. This creates a protein that binds to Runx1 target genes but can 
only repress these genes. From this observation it appears that Runx1 functions 
mainly as a repressor in adult mice. From previous studies it is known that Runx1 
forms a repressive complex with mSIN3a in hematopoietic stem and progenitor cells 
(HSPS)[15], but nothing is known about this complex at later stages. 
We are interested in the function of Runx1 in adult erythropoiesis, because it was 
found to be present in a complex containing essential regulators of erythropoiesis like 
LDB1, GATA1 and TAL1[16-17]. Its protein partners and target genes were identified 
using mass spectrometry and ChIP-sequencing. A number of these Runx1 target 
genes are important for erythropoiesis and we show that Runx1 regulates these 
genes via Myef2, a previously unknown repressor important for erythropoiesis.
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Materials and methods
Tagging Runx1 construct
A Nhe1 restriction site was cloned into the cDNA of the Runx1 distal promoter to 
replace the translation start site. The Bio-V5 double tag was ligated into the Nhe1 
site to create N-terminally tagged Runx1 cDNA[18-20]. The tagged Runx1 cDNA 
was cloned into the Not1 site of the GATA1 minimal promoter[21-23]. 
Cell culture
Mouse Erythro-Leukaemia (MEL) cells were cultured in DMEM containing 10% fetal 
calf serum and penicillin/streptomycin. Addition of 2% dimethylsulfoxide (DMSO), 
was used to induce differentiation towards terminal erythrocytes. Cells were 
harvested after 4 days of differentiation.
Immunoprecipitations
N-terminally tagged Runx1 cDNA was stably expressed in MEL cells containing 
the bacterial biotin ligase BirA[24]. Nuclear extracts were made of MEL cells as 
described[24]. Immunoprecipitations (IP) were done as described [25]. Bio-V5-Runx1 
Immunoprecipitations (IP) from nuclear extracts were preformed using V5 affinity 
agarose beads from Sigma[16]. Antibody IP’s are described in the supplementary 
data S1. Washes were preformed using HENG150 0.3%NP40. IP’s were preformed 
in the presence of benzonase endonuclease to exclude the identification of complex 
formed via DNA binding. 
ChIP and ChIP-sequencing sample preparation
Chromatin Immunoprecipitations (ChIP) were performed using a sonication buffer 
as described[20]. Per ChIP 2x107 and per ChIP-seq 10x107 MEL cells were used. 
Antibodies used for ChIP are described in supplementary data S1.
shRNA in MEL cells
The TRC Mission human and mouse library from Sigma was used for shRNA 
mediated knock-down of proteins of interest. They were delivered to MEL cells via 
lentiviral infection. Virus was added to 0.5x106 MEL cells and cultured for 48 hours. 
Puromycin was added and nuclear extracts and/or total RNA was harvested 48 
hours later. For induced MEL cells DMSO was added to the medium together with 
the puromycin and cells were harvested 4 days later. 
Bio-informatical analysis
The bio-informatical analysis of the microarray and ChIP-sequencing data were 
carried out as described in[19].
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Results
Tagging Runx1 and generating stable MEL cell lines
The Runx1 protein was tagged with a Bio-V5-tag at the N-terminus by inserting 
the sequence coding for this tag at the 5’-end of the runx1 cDNA starting from the 
initiation of translation site of the distal promoter (Fig 1A) and the cDNA was stably 
expressed in BirA MEL cells using a GATA1 expression vector[24]. Several clones 
were tested to avoid potential overexpression artefacts and clone 7 was chosen 
because it gave low Bio-V5-Runx1 expression close to the endogenous levels 
(Fig 1B). Clone 7 also did not show a difference in normal or induced tissue culture 
compared to non transfected MEL cells. The immunoprecipitation (IP) of Bio-V5-
Runx1 is efficient because it is almost absent in the supernatant of the IP (Fig 1C).
Identifying Runx1 protein partners via V5 
immunoprecipitations and mass spectrometry
Single-step purifications of Bio-V5-Runx1 complexes were performed using V5-
agarose beads (Sigma) and analyzed by mass-spectrometry (LC-MSMS). Control 
V5-Immunoprecipitations were performed in BirA-MEL cells not containing the Bio-
V5-Runx1 vector. The mass spectrometry (MS) data (Table 1) show the proteins that 
that were pulled down with the Bio-V5-Runx1. These were not found in the control 
V5-IP. A number of proteins were pulled down that were previously found to interact 
with Runx1, e.g. CBFβ and GATA1[26-29], which shows that the tagged Runx1 
forms the appropriate complexes. As expected Eto2 and Tal1 were also found in the 
mass spec data confirming that Runx1 is part of the LDB1 complex in erythroid cells, 
although LDB1 itself was not found in our data. This suggests that Runx1 binds to 
this complex via Eto2 and/or Tal1. 
The LSD1 complex was also found, albeit only in differentiated cells. It contains LSD1, 
Gfi1b and Co-rest and has been shown to be important in haematopoiesis[30-31]. 
LSD1, the first demethylase identified in mammals, demethylates H3K4 to enable 
gene repression[32-33]. However recent evidence showed that LSD1 can also 
function as an activator by demethylating H3K9 via an as yet unknown mechanism 
[34-36]. The Runx1-LSD1 interaction was validated by immunoprecipitations using 
antibodies against endogenous Runx1 (Fig 2) and LSD1 (supplementary data S6). 
Also here the proteins were mainly found to interact in cells induced to differentiate.
Another potential repressor that was identified in the V5-IP data was Myelin 
expression factor 2 (Myef2) (Table1), which has not been shown previously to be 
expressed or form complexes in hematopoietic cells. Myef2 has been identified as 
a repressor of the mouse myelin basic protein gene and binds DNA directly[37]. It 
contains two RNA recognition motifs (RRM) that have been shown to be responsible 
for binding to DNA[38]. The binding of Myef2 to endogenous Runx1 was confirmed 
with antibody IP although only a weak band was visible, due to the quality of the 
antibody used, which results in an inefficient Runx1 endogenous IP (Fig 2). 
Supplementary figure S7 shows Myef2 binding to Bio-V5-Runx1 via the more 
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Figure 1. Bio-V5-Runx1 and V5 immunoprecipitation. A) Schematic view of Bio-V5-
Runx1. A Bio-V5 double tag was placed on the N-terminus of the Runx1 cDNA starting from the distal 
promoter. B) Expression of Bio-V5-Runx1 in MEL cells clone 7 and compared to endogenous levels of 
Runx1 in BirA control cells. C) The V5-IP was analyzed on western blots using anti-Runx1 or anti- V5 
staining. The VCP protein was used as loading control.
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efficient V5 IP. This shows that the Runx1-Myef2 complex is much more prominent 
in non-induced MEL cells. The interaction can be seen in induced cells but only with 
the more efficient V5-Runx1 IP and a longer exposure time (supplementary data S7). 
It was not possible to carry out the reverse IP for Myef2 with the presently available 
antibodies. Also a tagging approach at the N or C terminus of the Myef2 was also not 
successful.
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Table1. Mass spectrometry results Bio-V5-Runx1 V5 immunoprecipitation. (-) 
no binding found (+) strong binding found (+/-) medium binding found.
Figure 2. Confirmation of the mass spec data using endogenous Runx1 
immunoprecipitations. Rabbit anti-Runx1 and Rabbit control IgG IP of nuclear extracts form non-
induced and induced MEL cells and analysed by western blots stained for Runx1, LSD1 and Myef2.
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Genome wide Runx1 DNA binding sites 
The Bio-V5-tagged version of Runx1 was then used to identify the genome wide 
DNA binding sites of Runx1 by chromatin immunoprecipitations followed by 
sequence analysis of the bound DNA (ChIP-seq). The Runx1 +23.5 enhancer was 
used as a positive control for the ChIP[39] to show that the Bio-V5 tagged Runx1 
and endogenous Runx1 were bound to this enhancer (supplementary data S8). This 
site is also a prime binding site in the ChIP-seq analysis. In total 13 million reads 
were mapped back to the mouse genome. These genome wide binding data were 
combined with microarray data of differentially expressed genes in differentiating 
MEL cells[17] and visualised in Figure3a with on the x-axis the position of Runx1 
binding to the transcriptional startsite (TSS) of the differential expressed gene and 
the y-axis the fold expression change during differentiation. The bubbles in the plots 
are Runx1 binding sites and the size represents the peak height in the ChIP-seq 
data. The result shows that Runx1 binds to a significant number of genes that are up 
or down regulated upon differentiation in non-induced and induced MEL cells, many 
of which are involved in erythroid differentiation. Induced cells show less binding of 
Runx1 to upregulated genes, although the overall binding pattern does not change.
A motif discovery analysis in 200bp around Runx1 binding peaks shows a Gata1 
binding motif to be present at 74% of these peaks (Fig3b). Two other motifs were 
also seen to be overrepresented around Runx1 binding peaks, of course the E box 
binding Tal1 and an ets/elk/elf binding site.
Runx1 binding to erythroid specific genes
To verify the binding to regulatory elements of important or typical haematopoietic 
genes we checked binding to the genes gata1, eto2, and epb4.2. Gata1 is an 
important regulator of erythropoiesis and essential for the terminal differentiation 
(reviewed in [40]). Eto-2 was shown to be part of the Gata1/Ldb1/Tal1 complex 
in erythroid cells and its absence causes an erythroid phenotype in mice[16, 41]. 
Both the gata1 and eto2 gene were top hits in the Runx1 ChIP-seq data and are 
transcription factors. Gata1 binds DNA while Eto2 does not. Epb4.2 is a structural 
membrane protein of erythrocytes that is highly upregulated in differentiating 
erythroid cells (reviewed in [42]). It is not a transcription factor like Eto2 and Gata1 
and is an example, of Runx1 binding to a totally different type of gene in erythroid 
cells.
Table 2. Overlap binding of Runx1/Gata1 shown on Runx1 target genes. Number of 
genes and percentage of overlap total target genes Runx1 shown.
Overlap Runx1 and Gata1 binding
non-induced induced
Upregulated
genes
Down regulated
genes
Upregulated
genes
Down regulated
genes
Number of genes 745 553 130 123
Percentage of overlap 70.7% 57.4% 75.1% 38.8%
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Figure 3. Runx1 genome wide binding 
patterns A) Non-induced and induced MEL cells. With on 
the x-axis the position of Runx1 binding to the transcriptional 
startsite (TSS) of the differential expressed gene and the y-
axis the fold expression change during differentiation. The 
bubbles in the plots are Runx1 binding sites and the size 
represents the peak height in the ChIP-seq data. Brown 
bubbles: TSS in non CpG region. Green bubbles: TSS in 
CpG region B) Motif discovery analysis 200bp around 
Runx1 binding sites. Gata motif discovered around 72% of 
Runx1 binding site. Also the E-box sequence and ets/elk/
elf binding motief were discovered around Runx1 binding 
sites.
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Figure 4. Confirmation ChIP-sequencing results via endogenous Runx1 ChIP. 
ChIP preformed in MEL cells non-induced (NI) and MEL cells induced (I). A) Rabbit anti-Runx1 and 
Rabbit control IgG ChIP. RT-PCR done with primers against gata1 HS3.5 enhancer and negative region 
at 3’UTR gata1 gene. B) Rabbit anti-Runx1 and Rabbit control IgG ChIP, RT-PCR done with primers 
against eto-2 promoter and negative region 2kb downstream of startsite C) Rabbit anti-Runx1 and 
Rabbit control IgG ChIP, primers against epb4.2 promoter and negative region at 3’UTR epb4.2 gene.
Runx1 binds to the promoter of eto2 and epb4.2 and to the promoter and upstream 
erythroid HS-3.5 enhancer of gata1 (Fig4 a,b,c). This binding was observed in both 
non-induced and induced MEL cells. No binding was observed in the negative 
controls, the 3’UTR of the gata1 and epb4.2 gene and 2kb downstream of the eto2 
promoter.
Knock-down of Runx1 shows a function as a 
transcriptional repressor
Five Runx1 shRNA’s from the TCR library were tested by lentiviral infection 
followed by puromycin selection. Western blots of nuclear extracts showed that 
shRunx1#1 and shRunx1#2 transduction resulted in a knock-down (KD) of Runx1 
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in MEL cells versus the control shTCR (Fig5a). Microarray data of the non-induced 
and induced KD MEL cells (supplementary table S3 and S4) were correlated to the 
Runx1 ChIP-seq data to identify direct target genes and these are shown in Figure 
5b. Different genes are up- or down regulated before differentiation after a Runx1 
KD, which suggests that Runx1 can function both as an activator and repressor 
in erythroid cells. Runx1 appears to activate its own gene, but is a repressor of a 
number of others. Most shows a moderate increase of expression after the Runx1 
KD, but others such as Ebp4.2 show a dramatic increase in expression suggesting 
that Runx1 is the major repressor of this gene in undifferentiated cells. When the 
cells are differentiated much fewer genes are affected and to a lower extent which 
correlates with a decrease of bound Runx1. This suggests that its role in late 
erythroid differentiation is much less important. 
Previous results from our lab show that the full Gata1/Tal1/Ldb1 complex acts mainly 
as an activator in MEL cells. Recent data (unpublished) show that this activation 
during differentiation is primarily achieved through the release of repression in the 
undifferentiated cells. Runx1 binds to this complex of activators and may activate 
genes in MEL cells via this complex. The ChIP/seq profiles in Table2 show that the 
overlap in binding of Runx1 with Gata1 binding is highest in genes repressed by 
Runx1 consistent with the role of the Gata1/Tal1/Ldb1 complex.
Because the Runx1 protein levels were difficult to detect, the RNA expression 
levels were also measured using RT-PCR. The result (Fig6a) confirms that Runx1 
expression is indeed reduced in the MEL cells transduced with shRunx1#1 and 
shRunx1#2. Eto2, epb4.2 and gata1 expression was clearly increased in the Runx1 
KD samples before induction of differentiation.
The mass spec and IP data show that only Myef2 is bound to Runx1 in non-induced 
cells and that this binding is lost after induction. This suggests that Myef2 is the factor 
that represses transcription together with Runx1. 
Knock-down of Myef2 shows similar gene regulation as 
Runx1
The KD data above suggest Myef2 is the repressive co-factor of Runx1 before 
differentiation. To test this possibility shRNA vectors Myef2 were tested to determine 
if Myef2 is important in repression.
Fig 6b shows that the two shRNA vectors against Myef2 transcripts result in a 
KD of 50% or more in the undifferentiated MEL cells. This results in a doubling of 
the transcripts of the runx1, eto2, and gata1 genes, which corresponds with the 
repression that was also seen in the Runx1 KD and strongly suggests that Runx1 
represses these genes via Myef2. The transcripts of epb4.2 were much less 
dramatically increased compared to the Runx1 KD and will be elaborated on in the 
discussion. It is unfortunately not possible to determine whether Myef2 binds to 
the same site as Runx1 due to the quality of the Myef2 antibody. Nevertheless we 
conclude that Runx1 has a suppressive role only before induction and that this role 
is mediated via Myef2. 
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Figure 5. Genome wide identification of Runx1 
target genes A) Western blot shRunx1#1 and shRunx1#2 
versus shTCR control. Runx1 stain and VCP as loading control. B) 
Bubble plot representation of Runx1 ChIP-sequencing binding data 
to differentially expressed genes after Runx1 knock-down. With 
on the x-axis the position of Runx1 binding to the transcriptional 
startsite (TSS) of the differential expressed gene and the y-axis 
the fold expression change during differentiation. The bubbles in 
the plots are Runx1 binding sites and the size represents the peak 
height in the ChIP-seq data. Brown bubbles: TSS in non CpG 
region. Green bubbles: TSS in CpG region 
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The binding site of Myef2 is TGTCCT and it is expected that this site is more 
represented in Runx1 repressed genes when compared to the activated genes. 
Table 3 shows that indeed the Myef2 binding site is represented more in genes 
repressed by Runx1, confirming the observation that Runx1 represses erythroid 
genes via Myef2.
Discussion
One of the essential regulators in the emergence of the haematopoietic stem cell is 
the transcription factor Runx1. However the role of Runx1 beyond haematopoietic 
stem cell formation and maintenance in erythroid cells is poorly understood. In this 
study a previously unknown role of Runx1 in erythropoiesis is uncovered by showing 
that it acts as a repressor of a number of erythroid genes via the repressor protein 
Myef2. This function of Runx1 is very different from that described previously in 
primitive erythropoiesis in zebrafish, xenopus and mouse and makes use of the 
newly discovered partner protein Myef2 
Runx1 was known to have a function in the development of megakaryocytes, which 
develop from the same progenitor cell as erythroid cells and where Runx1 also 
functions as an repressor (reviewed in [43]). The complex of Runx1 and Gata1 has 
been described in megakaryocytes[28-29], but it is not clear what function it has 
during megakaryocytic development and whether a complex is formed with LSD1 or 
Myef2.
Figure 6. Knock-down experiments Runx1 and Myef2. Expression levels of mRNA were 
measured via quantitative PCR of Runx1, Myef2, Epb4.2, Eto-2 and Gata1 A) mRNA shRunx1 RT-PCR 
measured versus shTCR control in non induced MEL cells. B) mRNA shMyef2 RT-PCR measured versus 
shTCR control in non induced MEL cells. 
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The interaction of Runx1 with LSD1 was confirmed in MEL cells via co-IP with 
antibodies against Runx1 and LSD1 in both non-induced and induced cells. However 
when the IP is performed with an antibody against LSD1 the interaction is seen solely 
in induced MEL cells. This suggests that the interaction between Runx1 and LSD1 is 
stronger in induced MEL cells and possibly only needed in these cells. However the 
present data do not provide any direct evidence that this particular interaction has a 
function in the induced cells.
Table 3. Overlap Runx1 binding to target genes and Myef2 binding sequence 
“TGTCCT”. Number of genes and percentage of overlap total target genes Runx1 shown.
The interaction of Runx1 with Myef2 is seen in the mass spectrometry data from 
non-induced and induced cells with similar mascot scores. However an interaction 
was confirmed by an anti-Runx1 IP in non-induced cells only. This suggests that the 
interaction between Runx1 and Myef2 is much weaker or even lost after induction 
which may explain why the suppressive role of Runx1 on the target genes that 
were analysed is lost. The trigger of this disassociation is not known but a possible 
explanation could be the recruitment of LSD1 to Runx1.
It has been shown that Runx1 has a role in primitive erythropoiesis. In the 
Runx1-/- mouse the morphology of primitive erythrocytes is affected and Gata1 is 
down regulated, although it is not clear whether this downregulation is a primary 
effect or a secondary effect[11]. Here we show Runx1 binding to the gata1 locus 
and that Runx1 regulates Gata1 expression. If Runx1 would also bind the gata1 
locus and regulate the gene directly in primitive erythropoiesis it would do so as an 
activator and not as a repressor via Myef2. 
Our genome wide correlation of Runx1 ChIP-seq and KD suggests that Runx1 acts 
as a repressor and an activator in MEL cells. The complex that would be in part 
responsible for gene repression would be Runx1-Myef2. Most Runx1 target genes 
show a moderate increase of expression after the Runx1 KD, like gata1 and eto2. 
Others such as ebp4.2 show a dramatic increase in expression. This observation 
suggests that Runx1 is the major repressor of certain genes in undifferentiated cells 
and a less important repressor of other genes. 
Gata1 acts as an activator in MEL cells and also interact with Runx1. This complex 
could be responsible in part for Runx1 gene activation. We show however that these 
complexes are more present at genes repressed by Runx1 which corresponds 
with the recent observation that activation (by the Gata1-Tal1-LDB1 complex) 
during differentiation is primarily achieved through the release of repression in the 
undifferentiated cells. How Runx1 activates genes in MEL cells remains unclear 
from our data.
Overlap Runx1 and TGTCCT occurrence 200bp +/- of peak position
non-induced induced
Upregulated
genes
Down regulated
genes
Upregulated
genes
Down regulated
genes
Number of genes 451 339 81 101
Percentage of overlap 42.8% 35.2% 46.8% 31.9%
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Deletion of Runx1 in adult mice does gives extramedullary hematopoiesis composed 
of maturing myeloid and erythroid cells[9-10], suggesting an increase in activity at 
the precursor stages (as represented undifferentiated MEL cells). Runx1 may be 
even more essential for stress erythropoiesis. For example Eto2 which is part of the 
same complex is important for erythropoiesis in vitro and stress erythropoiesis in 
vivo[16-17, 41]. 
In summary we report a novel function of the Runx1 protein in erythrocyte 
development. It acts as a repressor of important erythroid genes like eto2, gata1 and 
epb4.2. The repression of these genes is mediated via Myef2 which we show to be a 
binding partner of Runx1. The repressive function of Runx1 and the complex binding 
with Myef2 are lost after induction of differentiation. This suggests that Runx1 keeps 
erythroid specific genes repressed before terminal differentiation 
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Abstract
Runx1 is essential for the emergence of the definitive haematopoietic stem cell and 
plays a role in haematopoiesis thereafter. Runx1 binds and regulates a number of 
important erythroid genes in combination with Myef2. In order to further investigate 
the role of Myef2 in haematopoiesis morpholino knock-down studies were performed 
in zebrafish embryos. These experiments show that Myef2 has an important role in 
zebrafish erythropoiesis and T-cell development presumably mediated via Runx1.
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Introduction
Runx1 is important in the development of the definitive haematopoietic stem cell 
(HSC) in e.g. mouse and zebrafish[1-3]. Later in development Runx1 is important in 
the differentiation of the HSC into T-cells and erythrocytes[4-5][van Riel et al]. How 
Runx1 functions after the emergence of the definitive HSC, and in particular in the 
erythroid compartment, is largely unknown. It is known to function as a transcriptional 
repressor and activator on different genes. Runx1 activates for example the pu.1 
gene early in definitive haematopoietic development and later in development the 
CSFR gene[6-7]. Runx1 can form activating complexes with p300, a histone acetyl 
transferase[8]. It has been shown that Runx1 represses the cd4 gene[9-10] in the 
development of T-cells probably via a repressive complex formed with Groucho/
TLE[10]. From previous studies it is also known that Runx1 forms a repressive 
complex with mSIN3a in hematopoietic stem and progenitor cells (HSPS)[11].
Myelin expression factor 2 (Myef2) has previously been identified as a repressor 
of the mouse myelin basic protein gene and it was shown to bind DNA directly[12]. 
Myef2 contains two RNA recognition motifs (RRM) that have been shown to be 
responsible for binding to DNA[13]. It was recently identified by us as a partner of 
Runx1 in erythroid cells and shown to repress important erythroid genes[vanRiel 
et al], which was surprising as it had not been shown to be expressed or form 
complexes in haematopoietic cells previously.
In order to further study its role in haematopoiesis we carried out an oligonucleotide 
morpholino knock-down of Myef2 in zebrafish. This results in an erythroid and T-
cell phenotype in the definitive haematopoiesis, which shows that Myef2 indeed has 
an important role in zebrafish haematopoiesis which is presumably mediated via 
Runx1. 
Materials and methods
Zebrafish maintenance and morpholino injections
Fish were bred and maintained as described[14] and staged as described[15]. 
Morpholino oligonucleotides (MO) were designed to target splice junctions in the 
un-spliced myef2 messenger RNA: Myef2 MO 5’-CTCACCAACTACATGAGACATA
CAA-3’, targeting the intron2-exon3 junction. Typically, 1nl of MO were injected in 
1-2 cell stage embryos (Myef2 MO – 6.5ng/nl) and their efficiency verified by PCR 
with the following primers: myef2 F- CAGAACCAAGACGACACGAA and myef2 R- 
CGATGGATGGAGGAATGTTT. 
Whole mount in situ hybridization
Whole mount in situ hybridization was carried out as described [16]. DIG-labelled 
antisense RNA probes were transcribed from linearized templates using T3, T7 or 
Sp6 RNA polymerases (Roche, Burgess Hill, United Kingdom). After hybridization, 
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embryos were bleached in 5% formamide, 0.5% SSC, 10% H2O2 for 10-30 minutes, 
washed in PBST (PBS, 0.1% Tween-20) and transferred to 80% glycerol for 
imaging.
Results
Myef2 morpholino injected zebrafish show low Runx1 
and Gata1 mRNA levels
Myef2 zebrafish knock-down experiments were carried out to verify a potential role 
of Myef2 in haematopoiesis. A splice MO was injected into the zebrafish zygote. 
Figure 1a shows that it targets Myef2 mRNA because an extra band appears in the 
PCR analysis of Myef2 mRNA when compared to the control shown by the yellow 
arrow. This extra band is alternatively spliced mRNA that cannot be translated into 
functional protein. The mRNA of the housekeeping gene ef1α is unchanged. 
mRNA levels of a number of haematopoietic genes expressed in developing 
zebrafish were visualized by in situ hybridization. Runx1 and Gata1 mRNA were 
stained 20 hours post fertilizations (hpf) which is the period of time that the primitive 
hematopoietic system develops. Figure 1b shows that the levels of Gata1 and Runx1 
mRNA are unchanged in the MO injected zebrafish when compared to wildtype. 
Figure 1c shows that the Runx1 levels are much lower when compared to wildtype 
after 26hpf which represents the onset of the definitive haematopoietic system. Four 
days post fertilization (dpf) also shows a drop in Gata1 expression when compared 
to wildtype resulting in a defective erythropoiesis. 
Myef2 phenotype is limited to the haematopoietic 
system
Closer examination of the expression patterns in the early development of 
zebrafish haematopoietic system shows that the expression levels of cMYB, 
Fli1, Ikaros, Pax2.1 and deltaC seem to be normal at the onset (28hpf) of the 
definitive hematopoietic system (Figure 2a). cMYB is essential for mouse definitive 
haematopoiesis but it is also expressed during primitive haematopoiesis[17-18]. 
In zebrafish cMYB is expressed in the ventral wall of the dorsal aorta in Runx1 
positive cells[19]. Ikaros is also detected in primitive and definitive haematopoietic 
precursors in both mice and zebrafish[20-21] and is essential for development of all 
B- and T-cell lineages[22]. Fli1 is expressed in the primitive and definitive stage of 
haematopoiesis is zebrafish[18] and is, together with deltaC, essential for normal 
vascularisation needed for haematopoietic development[23]. Figure 2a show 
that this vascularisation is unaffected in the MO injected zebrafish. In addition the 
development of the pronephric duct is unaffected as shown by normal expression 
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Figure 1 Zebrafish splice morpholino injections against zebrafish Myef2.
A) PCR on Myef2 and housekeeping gene ef1α  mRNA. In MO injected zebrafish an extra PCR band 
was seen, that represents spliced mRNA under the influence of the MO (yellow arrow), compared to the 
control. B) Staining of Gata1 and Runx1 at 20hpf, which represents primitive haematopoiesis. C) Staining 
of Runx1 26dpf and Gata1 4dpf which represent definitive haematopoiesis
of PAX2.1[24]. By 4dpf the definitive HSC migrate to the kidney marrow and remain 
there throughout the zebrafish lifespan. Malformations in its development could 
explain haematopoietic phenotypes. Thus the results show no haematopoietic 
phenotype in the Myef2 MO injected zebrafish in the early stages of definitive 
haematopoiesis apart from the low levels of Runx1 (Fig1c).
Figure 2b shows the expression levels of Rag1 and Ikaros (T-cell markers) at 4dpf 
in the zebrafish thymus[22, 25]. No or very few T-cells are present in the thymus of 
MO injected zebrafish when compared to the controls, which show a clear T-cell 
staining. Furthermore we see less staining of cMYB in the kidney marrow of MO- 
treated zebrafish that represents lower amounts of HSC.
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Figure 2 Zebrafish splice morpholino injections against zebrafish Myef2.
A) Staining of cMYB, Ikaros and Fli1 to show HSC development. Staining of Fli1, Pax2 and deltaC to show 
morphology of haematopoietic tissue. Staining at 28hpf represents the onset of definitive haematopoiesis. 
B) Staining of rag1 and Ikaros (T-cell markers) in the thymus and cMYB (HSC marker) in the kidney 
marrow at 4dpc. 
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Discussion
One of the essential regulators in the emergence of the haematopoietic stem cell is 
the transcription factor Runx1. However the role of Runx1 beyond haematopoietic 
stem cell formation and maintenance in erythroid cells is poorly understood. In this 
study we show that a previously unknown partner of Runx1, named Myef2, has an 
important role in haematopoietic development in zebrafish.
A haematopoietic phenotype was observed in the zebrafish injected with MO 
against Myef2 mRNA. A striking observation was that no effect could be seen in the 
development of the primitive haematopoietic system similar to what is observed 
in Runx1 knock-out mice and zebrafish knock-down studies[1-3]. The levels of 
Gata1 and Runx1 were both comparable to the control. When the levels of Runx1 
and Gata1 were measured in definitive haematopoiesis the levels were lower in 
the zebrafish injected with the MO against Myef2 compared to the control resulting 
in less definitive HSC seen at 4dpc by cMYB staining. This phenotype is probably 
caused due to the lower levels of Runx1 caused by the lower levels of its partner 
protein Myef2. The lower Gata1 levels seen in 4dpc in the kidney marrow indicates 
a erythroid phenotype that corresponds with the role of Runx1 and Myef2 seen in 
mouse erythropoiesis [van Riel et al]
When the phenotype was investigated further the levels of haematopoietic markers 
like cMYB, FLI1 and Ikaros were indeed normal during the early stages of definitive 
haematopoiesis. This suggests that the development of the haemogenic endothelium 
is unaffected by the Myef2 KD, but that becomes important later. The morphology of 
the vascular system and the pronephric duct were also normal as shown by Fli1, 
Pax2 and DeltaC staining and we therefore conclude that the phenotype seen in the 
MO injected zebrafish is not due to morphological defects in kidney development. 
At 4dpf the levels of T-cell markers Rag1 and Ikaros are almost undetectable in the 
thymus. Runx1 is known to have an important role in T-cell development [5, 10, 26] 
and we therefore hypothesize that the T cell phenotype seen with Myef2 deficiency 
is the same as seen with a loss of Runx1.
We conclude that number of definitive HSC is lower due to improper Runx1 function 
via Myef2. Similarly the development of erythrocytes and T-cells is probably also 
aberrant due to improper Runx1 function.
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Abstract
The haematopoietic transcription factor Runx1 is important for the differentiation 
of T-cells, B-cells, megakaryocytes and erythrocytes. Most of these observations 
were made using mouse knock-out studies and give little information about the 
molecular mechanisms. Here we show that Runx1 forms a complex with the histone 
modification enzyme LSD1 in erythroid cells. LSD1 is recruited via Runx1 to genes 
in erythroid cells and appears to be involved in the repression of these genes.
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 Introduction
Runx1 is an important transcription factor in the differentiation of the haematopoietic 
stem cell towards T-cells, megakaryocytic and erythrocytes[1-3][vanRiel et al], but 
the molecular mechanism how and which genes are regulated by Runx1 during 
differentiation is largely unknown. Using Mouse Erythro-Leukaemia (MEL) cells it 
has been shown that Runx1 represses a number of erythroid genes like epb4.2, 
gata1 and eto2 in the proerythroblast state of terminal differentiation[vanRiel et al]. 
Very little is known how Runx1 activates genes in the proerythroblast stage and 
during the downstream erythroid differentiation. 
Histone tails can be modified in several different ways, like methylation, 
phosphorylation and acetylation, and have been associated with transcription 
regulation[4-8]. The methylation of histones lysine residues in the tails can be 
mono-, di- or tri-methylated. Histone methylation is associated with both gene 
activation and repression and is recognised by the chromodomain that is associated 
with chromatin remodelling proteins[9]. Histone methylation was thought to be a 
permanent epigenetic mark until a histone demethylase was discovered called 
Lysine Specific Demethylase1 (LSD1)[10-11]. LSD1 demethylates H3K4 mono and 
di-methylation that results in gene repression. Recently evidence has been found 
that LSD1 may also function as an activator by demethylating the repressive mono 
and di-methylation mark on H3K9[12-14]. LSD1 was shown to be important in 
erythropoiesis and LSD1 depleted MEL cells do not differentiate properly towards 
terminal erythrocytes[15-16]. These studies also showed Tal1 and Gfi1b to regulate 
erythroid genes via LSD1. Our lab showed that Runx1 is in the same complex with 
LSD1, Tal1 and Gfi1b in erythroid cells[17][vanRiel et al]. 
Here we investigate whether the Runx1-LSD1 complex functions as a histone 
demethylating complex after differentiation of MEL cells i.e. during terminal erythroid 
differentiation after the proerythroblast stage. We used RNAi knock-down and 
ChIP-sequencing studies to identify genes regulated by Runx1. We show that the 
binding of LSD1 to Runx1 repressed genes is upregulated during terminal erythroid 
differentiation and appears to be involved in their repression.
Materials and methods
Cell culture
Mouse Erythro-Leukaemia (MEL) cells were cultured in DMEM containing 10% fetal 
calf serum and penicillin/streptomycin. These cells represent the proerythroblast 
stage in erythropoiesis. Addition of 2% dimethylsulfoxide (DMSO), was used to 
induce differentiation towards terminal erythrocytes. Cells were harvested after 4 
days of differentiation.
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ChIP and ChIP-sequencing sample preparation
Chromatin Immunoprecipitations (ChIP) were performed using a sonication buffer 
as described[18]. Per ChIP 2x107 and per ChIP-seq 10x107 MEL cells were used. 
Antibodies used for ChIP are described in supplementary data S1.
shRNA in MEL cells
The TRC Mission human and mouse library from Sigma was used for shRNA 
mediated knock-down of proteins of interest. They were delivered to MEL cells via 
lentiviral infection. Virus was added to 0.5x106 MEL cells and cultured for 48 hours. 
For induced MEL cells DMSO was added to the medium together with the puromycin 
and cells were harvested 4 days later.
Bio-informatical analysis
The bio-informatical analysis of the microarray and ChIP-sequencing data were 
carried out as described in[19]. ChIP-sequencing data is shown in the UCSC genome 
browser with on top the gene of interests. Transcription factor and modified histones 
localization on chromosome are shown via peaks. Height of the peak represents 
number of sequences enriched in ChIP. Scores before and during differentiation 
are normalized to each other with the total amount of sequences found in the ChIP-
sequencing.
gene symbol chromosome logFoldChange
adjusted P
value
Ppbp 5 3.13289 0.016281
Acp5 9 2.47846 0.012924
Aqp8 7 2.26321 0.016281
Csf2rb2 15 2.00402 0.034224
Mybpc3 2 1.99324 0.012924
Pkhd1l1 15 1.95249 0.057030
Speer4d 5 1.67309 0.022900
Rph3al 11 1.61124 0.048133
Cd59a 2 1.58084 0.026256
Mt2 8 1.55024 0.020874
Pfkp 13 1.54721 0.055885
Aldoc 11 1.48925 0.043525
Rogdi 16 1.46784 0.016281
Hba-x 11 1.38273 0.016281
Csf2rb 15 1.37419 0.052173
Prokr1 6 1.35853 0.023114
Cntn3 6 1.35306 0.016281
Ube2l6 2 1.34797 0.016281
Tcp11l2 10 1.31306 0.030923
Sly Y 1.28335 0.044876
Art4 6 1.28204 0.048186
Ccng2 5 1.26220 0.042861
Man2b1 8 1.25007 0.016281
Table 1: Selection of upregulated genes Runx1 KD induced MEL cells
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Rogdi gene
Chip- sequencing
Runx1 non-induced
Runx1 induced
LSD1 non-induced
LSD1 induced
Tal1 non-induced
Tal1 induced
1
1
1
1
1
1
79
116
67
205
62
357
chr 16
2 kb
Figure 1: Runx1, LSD1 and Tal1 binding to Runx1 repressed gene rogdi in 
induced MEL cells: ChIP-sequencing data is shown in the UCSC genome browser with on top the 
gene of interests. Transcription factor binding in the region of the relevant gene are shown by the peaks. 
The height of the peak represents the number of sequences enriched in ChIP-sequence and hence is 
representative of the relative amount of Runx1 or LSD1 bound.
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Figure 2: Runx1, LSD1 and Tal1 binding to Runx1 activated gene prepl in 
induced MEL cells: ChIP-sequencing data is shown in the UCSC genome browser with on top the 
gene of interests. Transcription factor binding are shown as described in figure 1.
Chip- sequencing
Runx1 non-induced
Runx1 induced
LSD1 non-induced
LSD1 induced
Tal1 non-induced
Tal1 induced
1
1
1
1
1
1
Prepl gene
Chr 17
48
48
29
35
8
32
10 kb
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Results
Knock-down of Runx1 after the proerythroblast stage 
shows that a small group of genes is upregulated.
In order to investigate which genes are regulated by Runx1 in induced MEL cells RNA 
expression levels were analysed using microarray based experiments on induced 
MEL cells after Runx1 shRNA knock down (KD). The entire microarray data is shown 
in supplementary table S4. Table 1 shows that the expression level of 23 genes has 
increased by the knockdown when compared to control suggesting that these are 
repressed by Runx1 during the differentiation of MEL cells. Other genes show the 
opposite pattern and are downregulated by the Runx1 KD. Many of these genes 
are also bound by Runx1 on or near the transcriptional start site (TSS) (visualised in 
Chapter 2 Fig 5b). Because Runx1 forms a complex with LSD1 during differentiation 
suggests that LSD1 plays a role in these two sets of genes and that the patterns of 
histone methylation may change differently in the sets after differentiation of the MEL 
cells. We therefore analysed the binding of Runx1 and LSD1 to these genes and 
compared this to the distribution of H3K4 methylation marks at these genes. 
LSD1 and Tal1 are recruited to Runx1 repressed genes 
in differentiating MEL cells
ChIP-sequencing was carried out in MEL cells before and after differentiation for 
LSD1, Tal1, Gfi1b and a number of histone H3K4 mono- and di-methylation marks 
using antibodies specific for these factors or epigenetic marks. Runx1 ChIP-
sequencing was preformed using a V5 ChIP of an N-terminal Bio-V5 tagged Runx1. 
The data were analysed and displayed in the UCSC genome browser[20]. Figure 1 
shows detailed examples of the binding of Runx1 and LSD1 to the gene rogdi. This 
gene is upregulated in induced MEL cells in the Runx1 KD (Table 1). The results 
show that Runx1 binds in the second intron of the gene in close proximity to the TSS 
together with LSD1 both in non-induced and induced MEL cells. However in contrast 
to Runx1, which shows only a small increase, the binding of LSD1 increases more 
that 3 fold during differentiation. Figure 1 also shows an increase of Tal1 binding 
of almost 6 fold in agreement with the observation that Tal1 binding increases in 
general (Andrieu/Soler et al in prep). Tal1 and LSD1 have been shown to be partners 
in erythroid cells and that LSD1 is not recruited to genes by Tal1 during differentiation 
[16]. We propose that the elevated LSD1 level of binding is caused by the binding 
of LSD1 to Runx1. This corresponds with previously shown data where we show 
an increase in binding of LSD1 to Runx1 during erythroid differentiation[vanRiel et 
al]. This suggests that the recruitment of LSD1 by Runx1 to these genes may be 
responsible for their repression.
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If true it would be expected that the genes which are downregulated due to the 
Runx1 KD would not show a change (or even a decrease) of LSD1 binding during 
differentiation. An example (Figure 2, see also supplementary table S4 microarray 
data Runx1 KD differentiating erythroid cells) of such a gene is prepl which shows 
that Runx1 and LSD1 bind to these genes in non-induced and induced MEL cells at 
comparable levels. Tal1 binding is upregulated from no binding at all to a low level of 
binding.
LSD1 recruitment correlates with loss of histone 
methylation of Runx1 repressed genes in differentiating 
cells
Table 2 shows the binding scores of Runx1, LSD1, Tal1, Gfi1b and histone H3K4 
mono-, di- and tri-methylation marks of the ten most up and down regulated genes 
in differentiation cells depleted of Runx1. All these genes have a Runx1 binding site 
within 10kb of the gene locus. The table also shows ten genes that bind Runx1 but 
are not regulated by Runx1. LSD1 is recruited to all ten genes, Tal1 in eight of the ten 
and Gfi1b in eight of the ten most upregulated genes. In the ten most downregulated 
genes we show that LSD is recruited to four genes, Tal1 to two genes and Gfi1b 
to six genes. Finally ten of the genes not regulated by Runx1 show that LSD1 is 
recruited to seven genes, Tal1 to four genes and Gfi1b to seven genes. 
Almost all the genes that are repressed by Runx1 and show LSD1 binding show 
a decrease in H3K4 mono- and di-methylation, while tri-methylation remains 
unchanged, suggesting that LSD1 has a role in the Runx1 mediated repression 
during differentiation. The obvious next experiment would be to reduce the 
level of LSD1 during MEL cell differentiation, however LSD1 depleted MEL cells 
(supplementary figure S5) do not differentiate properly and hence it was not possible 
to obtain meaningful expression arrays of induced MEL cells with low levels of LSD1. 
It is therefore difficult to determine whether LSD1 and histone demethylation play a 
role in this group of genes because there is no correlation with the genes being up- 
or down-regulated during differentiation. There is however a reasonable correlation 
with LSD1 binding and a decrease of histone mono- and di-methylation of H3K4.
There is a clear correlation between the genes that are activated by Runx1 and 
downregulation during development. However there is only a weak correlation with 
decreased mono- and di-methylation of H3K4. There is no correlation with LSD1 
binding in this group, except that the binding is very low before and after induction. 
Clearly this group is regulated by Runx1 but not LSD1. 
In the group of genes that binds Runx1 but is not regulated by it there appears to 
be no correlation between histone methylation and the up- or down regulation of 
expression during differentiation. There is however some correlation between 
increased LSD1 binding and H3K4 mono- or di-demethylation.
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Discussion
Runx1 is known to regulate genes important for erythropoiesis in the proerythroblast 
[vanRiel et al]. After differentiation of the proerythroblast stage it was shown that 
Runx1 still regulates a number of genes, although this number is much smaller 
[vanRiel et al]. We have previously shown that Runx1 forms a complex with LSD1 
in induced MEL cells. Here we have investigated whether the Runx1-LSD1 complex 
regulates any genes during terminal erythropoiesis using ChIP-sequencing and 
knock-down studies.
As shown by the microarray data and the results in Chapter 2 it is clear that Runx1 
activates and represses a number of genes in induced MEL cells. This number is 
much smaller when compared to the number of genes that are regulated by Runx1 in 
non-induced cells. Many of these genes, such as rogdi, have an unknown function, 
but others have a known role in haematopoiesis in general or in erythropoiesis 
specifically. For example the ppbp gene (Pro-Platelets basic protein) is repressed 
by Runx1 in induced MEL cells and encodes the chemokine Cxcl7 in platelets[21-
22]. Also the pfkp gene (Phosphofructokinase platelets), which is highly expressed 
in megakaryocytes and platelets and important for glycolysis[23]. The csf2rb2 gene 
(colony stimulating factor 2 receptor, beta 2) encodes a common subunit of the IL-
3 (interleukin 3) receptor[24]. The il-3 gene is regulated by Runx1[25-26], however 
we find no binding of Runx1 to the il-3 gene in MEL cells (vanRiel et al unpublished 
data). IL-3 represses erythroid differentiation by inhibiting the erythroid regulatory 
factors produced via erythropoietin (EPO) (reviewed in [27]). The csf2rb gene (colony 
stimulating factor 2 receptor beta) which is also repressed by Runx1 (table 1), is part 
of the IL-3 receptor. These results show that Runx1 is involved in the repression of 
genes that are important for other haematopoietic lineages or genes that themselves 
inhibit erythroid differentiation.
The Runx1 DNA binding pattern does not change much during differentiation from 
proerythroblast towards erythrocytes, however the protein complexes formed 
with Runx1 do change during erythroid differentiation [vanRiel et al]. In particular 
the Runx1-LSD1 complex is mainly formed in induced MEL cells, suggesting that 
LSD1 may be the functional component of Runx1 in at least a subset of the genes 
repressed by Runx1. Indeed LSD1 binding increases at all of the genes repressed 
by Runx1 in induced MEL cells, however this was also seen in genes not regulated 
but bound by Runx1. The first group also shows an increase Tal1 binding to these 
genes in differentiating MEL cells. The possibility remains that both are needed by 
Runx1 to repress these genes. 
We show in Table 2 that the H3K4 mono- and di- methylation mark is reduced in most 
genes repressed by Runx1 although the mark does not disappear. We also show 
that the di-methyl mark is reduced in the majority of Runx1 activated genes while 
the mono-methyl mark is reduced in most non Runx1 regulated genes. In the top 
ten Runx1 repressed genes the changes in methylation marks correlate strong with 
the increased binding of LSD1. However these changes do not correlate with the 
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General discussion
Defects in erythropoiesis lead to reduced numbers or dysfunctional erythrocytes 
and causes diseases like anaemia, thalassemia and sickle cell anaemia. By 
understanding the molecular mechanisms involved in erythropoiesis novel therapies 
may be developed. In these studies the Mouse Erythro-Leukaemia (MEL) cell line 
was used as a model system of terminal erythroid differentiation in order to identify 
transcription factors involved in this process. MEL cells represent the proerythroblast 
stage and can be induced to differentiate towards terminal erythrocytes. 
The transcription factor Runx1 is important for the development of the definitive 
haematopoietic stem cell (HSC), T-cells, B-cells and megakaryocytes[1-6]. 
Erythrocytes and megakaryocytes develop from a common precursor cell called 
the Megakaryocyte-Erythrocyte Progenitor (MEP) cell[7-9] and the hypothesis was 
that Runx1 functions as a molecular switch between these two cell types[10]. This 
idea is supported by the observation that Runx1 transcription is downregulated 
during erythropoiesis[11-12]. Expression of Runx1 would push the MEP towards 
the megakaryocyte direction while Runx1 downregulation would result in erythroid 
differentiation. However this hypothesis was never proven experimentally. Our lab 
identified Runx1 to be part of a large protein complex in MEL cells. This complex 
also contains proteins like Gata1, LDB1 and Tal1 that are important for erythroid 
development and this complex was shown to regulate erythroid genes[13-16].
Runx1 is also known as AML1 because its gene locus is often translocated in acute 
myeloid leukaemia (AML)[17-18]. The most common translocation is the t8;21 that 
creates a fusion protein of the DNA binding Runt-domain of Runx1 and almost 
the entire eto gene[19]. Eto contains four conserved nervy homology regions that 
recruit corepressors such as N-coR, mSIN3a and also HDAC’s[20-22]. This AML1-
ETO fusion protein binds to Runx1 target genes and represses these genes[23-24]. 
Patients with an AML1-ETO translocation often show a hypoplasia, resulting in a 
disruption of erythroid and megakaryocytic differentiation[25]. This observation is also 
seen in mouse models expressing the AML1-ETO fusion protein[26]. Contradictory 
to these results is that a different AML-ETO mouse model does not show the 
hypoplasia phenotype[27]. These two mouse models are generated differently what 
could account for the difference shown. Also is the erythroid phenotype shown in 
older mice than tested in the mouse model not showing a phenotype. Furthermore 
it has also been shown that AML1-ETO inhibits the differentiation of K562 cells, 
MEL cells and human primary erythroid cells in vitro [28-30]. These results and the 
observation that Runx1 is part of a protein complex important for erythropoiesis 
suggest it has a role in this process.
Chapter 2 describes the DNA binding sites in the proerythroblast and differentiated 
cells of a Bio-V5 tagged version of Runx1 using ChIP-sequencing. Analysis of the 
DNA sequence around these binding sites showed an overrepresentation of Gata1 
and Tal1 binding sequences confirming that these transcription factors cooperate at 
the DNA level. The genome-wide comparison of Runx1 binding sites around or in the 
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differentially expressed genes in proerythroblast and differentiated cells shows that 
Runx1 binding to erythroid genes does not change much during terminal erythroid 
differentiation. The same analysis but with expression data from Runx1 depleted 
cells shows that Runx1 functions as an activator and a repressor in both stages but 
the number of affected genes is greatly reduced later in differentiated cells. A mass 
spectrometry screen of immunoprecipitated Bio-V5-Runx1 was used to identify the 
partners of Runx1 in the proerythroblast and differentiated MEL cells. This confirmed 
the presence of the proteins that are part of the LDB1 complex, like Gata1 and 
Tal1, but not LDB1 itself. This suggests that the binding of LDB1 and Runx1 is very 
indirect and probably mediated via another factor in the complex. This analysis also 
identified the new partners Myef2 and LSD1. Myef2 was originally shown to be a 
repressor of the mouse myelin basic protein gene and binds DNA directly via the 
sequence “TGTCCT”[31-32], while LSD1 was the first demethylase identified and 
functions as a repressor by removing the H3K4 mono- and di-methylation marks 
associated with gene activity[33]. Such lysine methylation marks are recognised by 
the chromodomain associated with chromatin remodelling proteins[34].
Suppression of Runx1 by RNAi shows that it represses important erythroid genes 
like epb4.2, gata1 and eto2 at the proerythroblast stage. This repression is lifted 
when MEL cells are induced to enter terminal erythroid differentiation. The binding 
data show that Runx1 is bound to these genes before and after differentiation but 
that the binding with Myef2 is lost when cells differentiate. Knock-down of Myef2 
shows repression of the mentioned genes at the proerythroblast stage but not in the 
differentiated cells similar to the results obtained with the Runx1 knock-down. These 
results suggest that Runx1 needs to be bound to Myef2 in order to repress these 
genes.
The Runx1 RNAi induced knock down shows that the transcription of epb4.2 is 
upregulated 20 times while the transcripts of gata1 and eto2 only increase two-
fold. When Myef2 is knocked down all these three genes are upregulated only 1.5 
to 2 times. This appears to be a contradictory result because if all three genes are 
regulated by the Runx1-Myef2 complex a higher upregulation of the epb4.2 gene 
would be expected in the Myef2 knock-down. One possible explanation for this may 
be that another factor is involved in the suppression of epb4.2 that itself is regulated 
by the Runx1 complex. Another possible explanation is that the levels of Runx1 are 
actually not lowered in the Myef2 KD (it shows higher transcript levels of Runx1), 
resulting in more Runx1 loaded onto the genes using the remaining Myef2 protein 
pool more efficiently which may be resulting in a mild effect on the epb4.2 gene in 
the Myef2 KD. It was unfortunately not possible to perform immunoprecipitations 
and chromatin immunoprecipitations of Myef2 due to the poor quality of the available 
antibodies. To resolve this question new antibodies would have to be raised and 
tagging Myef2 would be the other option to help identify Myef2 partners and target 
genes. 
Myef2 was unknown to have a function in erythropoiesis or haematopoiesis and 
its potential role in haematopoiesis was therefore tested by morpholino mediated 
knock down in zebrafish (Chapter 3) and coupled to in situ hybridizations to visualize 
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mRNA expression of important haematopoietic genes. The results show no effect in 
primitive haematopoiesis, similar to Runx1 knock-down in zebrafish and mouse[6, 
35]. However with the onset of definitive haematopoiesis Runx1 mRNA levels are 
lower when compared to control probably as a result of a decreased number of 
cells rather than a decrease in Runx1 transcription. The levels of haematopoietic 
markers like cMYB, Ikaros and Fli1 are unchanged and also the morphology is 
unaffected shown by staining by deltaC and Pax2.1. These results suggest that the 
development of the haemogenic endothelium and the HSC is normal until Myef2 
is needed. We suggest that this would occur late in HSC development because of 
the levels of haematopoietic markers are normal or even downstream of the HSC. 
It would be interesting to investigate whether the loss of Myef2 would have a similar 
phenotype in the mouse and when exactly Runx1 is needed in the development from 
the haemogenic endothelium to HSC. 
At later stages in development a clear phenotype is seen. Less HSCs are present 
in the kidney marrow and the remaining cells appear to have a differentiation defect 
towards myeloid and lymphoid cells, since T-cells and erythroid cells are affected. 
Runx1 plays a role in the differentiation of both lineages in the mouse (Chapter 2 
and [27, 36-37]) and it would therefore seem reasonable to assume that the Myef2 
morpholino phenotypes seen in zebrafish are mediated via Runx1.
Runx1 and LSD1 occur in a complex during terminal erythropoiesis after the 
proerythroblast stage (Chapter 2). What triggers this complex formation is unknown 
but Runx1 is dephosphorylated in induced MEL cells (vanRiel et al, unpublished 
data). Eto2 is also part of the complex with Runx1 in induced MEL cells and this is a 
direct partner of LSD1 (Baymaz et al., unpublished data). Possibly LSD1 is recruited 
to Runx1 via Eto2. This could be proven by knock down of Eto2 or expressing a 
non LSD1 binding mutant and perform immunoprecipitations of Runx1 in these 
conditions to test if LSD1 is still a partner. 
The ChIP-sequencing results show that  Runx1 and LSD1 DNA binding sites overlap 
in genes repressed by Runx1 in induced MEL cells. Moreover the binding peaks 
of LSD1 increase in induced MEL cells when compared to non-induced MEL cells 
correlating with LSD1 forming a complex with Runx1. This suggests that  LSD1 is 
recruited to the DNA by Runx1 binding and would agree with the observation that 
LSD1 and Runx1 are part of a complex that is dynamic during differentiation[14][S
oler et al unpublished data]. However other explanations are possible, for example 
the increase in LSD1 bound sequences in induced MEL cells may simply be due 
to better availability of the epitope of the anti-LSD1 antibody. To control for this 
particular explanation, the ChIP-seq should also be repeated with a second antibody 
recognising a different epitope or with a tagged version of LSD1. However genes 
activated by Runx1 do not show an increase in LSD1 occupancy in induced MEL 
cells suggesting that the effect is not an experimental artefact and these genes are 
not regulated by LSD1.
The higher LSD1 occupancy correlates with a reduction in H3K4 mono- and di-
methylation in Runx1 repressed genes in induced MEL cells. Such reduction would 
lower the recruitment of chromatin remodelling factors and result in the repression 
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of the target gene. The methylation change however does not correlate with the 
changes in expression during differentiation of these genes. It is therefore difficult 
to determine if methylation changes play a role in the repression in any of these 
genes. To confirm this mRNA genome-wide expression levels and an analysis of the 
epigenetic marks should be carried out after LSD1 depletion in induced MEL cells. 
Unfortunately such an analysis could not be carried out because LSD1 depleted 
MEL cells do not differentiate properly[38] (data not shown). This problem may be 
solved by generating a system to deplete MEL cells of LSD1 in a rapid and inducible 
fashion[39] (Jorna et al unpublished).
It would also be interesting to study how LSD1 is recruited to particular Runx1 binding 
sites and not to others. A possible answer may be found in the DNA sequence of the 
different sites. For example this may show that other specific and cooperating factors 
are bound in the different classes of genes at or near the Runx1-LSD1 binding 
sequence which may for example stabilize the binding of LSD1 to the complex. 
Runx1 forms a complex with Myef2 and LSD1 (Chapter 2), but it is not clear whether 
the binding of these partners is direct or indirect and what domain(s) of the Runx1 
protein is important to form these complexes. These questions could be answered 
by co-immunoprecipitations of bacterially expressed versions of normal and mutated 
Runx1 and one of the partners. 
This work shows two modes of how Runx1 represses genes in terminal erythropoiesis 
but Runx1 also activates genes in the differentiation process (Figure 1), which would 
correlate with the observation Runx1 is associated with the Gata1/Tal1 complex of 
proteins, which mainly has an activating role in late erythroid differentiation [13,14]. 
However the comparison of Runx1 and Gata1 binding sites shows more overlap 
between binding sites in genes repressed by Runx1 (Chapter 2). This is in agreement 
with the finding that erythroid genes are activated by the LDB1/Gata1/Tal1 complex 
by a loss of repression rather than the recruitment of activators (Soler et al., 
unpublished data). However this still sheds no light on how Runx1 activates genes in 
erythroid cells. In other cell types Runx1 binds the acetyl transferase p300 that has 
been linked to transcription activation[40-41] but this protein was not found by us to 
bind Runx1 in erythroid cells. Since LSD1 has been reported to also demethylate 
H3K9 mono- and di-methylation marks[42], which correlates with gene activation it is 
tempting to speculate such a release of repression would be an obvious mechanism 
of how Runx1 mediates “activation” and would agree with the observation in Chapter 
4 that LSD1 binds to genes activated by Runx1 in induced MEL cells. However in 
chapter 4 is also shown that LSD1 does not regulate Runx1 activated genes.
In summary Runx1 plays an important role in the regulation of transcription during 
“late” erythroid differentiation and shows at least three modes of action. Two of these, 
the transcriptional suppression of particular genes in proerythroblast cells and the 
suppression of a set of genes in differentiated cells, are (at least in part) mediated 
by the co-factor Myef2 and (likely) LSD1 respectively. It is presently not clear how 
Runx1 activates genes during this late differentiation process, but it may in fact use 
LSD1 also for this process by demethylating the transcription factor themselves 
rather than demethylating histone H3. The next question to be answered would be 
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Proerythroblast Erythrocyte
Runx1-Myef2: gene repression
Runx1-?: gene activation
Runx1-LSD1: gene repression
Runx1-?: gene activation
Myef2 leaves complex
LSD1 enters complex
Figure 1 Model of Runx1 function in terminal erythroid differentiation
how these different processes are carried out by Runx1 and this presents a clear 
challenge for the next stage of unravelling this part of the erythroid transcriptional 
network.
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Antibody application company
catalogue
number
Rabbit anti-Runx1 ChIP, IP santa cruz sc-28679
Goat anti-Runx1 WB santa cruz sc-8563
Rabbit anti-LSD1
WB, ChIP-
seq Abcam ab17721
Rabbit anti-Myef2 WB Avia NP_057216
Mouse anti-VCP WB Abcam ab11433
Goat anti-Gfi1b ChIP-seq santa cruz sc-8559
Rabbit anti-Tal1 ChIP-seq santa cruz sc-22809
Normal Rabbit IgG ChIP, IP santa cruz sc-2027
Normal goat IgG ChIP, IP santa cruz sc-2028
Table S1. Antibodies used for experiments. Immunoprecipitation (IP), Western Blot 
(WB), Chromatin immunoprecipitation (ChIP)
ChIP Target gene Sequence
Amylase Reverse primer CTCCTTGTACGGGTTGGT
Forward primer AATGATGTGCACAGCTGAA
Gata1 HS3.5 Reverse primer CCGGGTTGAAGCGTCTTCT
Forward primer TCAGGGAAGGATCCAAGGAA
Gata1 3'UTR Reverse primer GAATAGCCTTGACCTTGTGGC
Forward primer GCAGGAGAATGGGAAATGTGG
Eto2 promoter Reverse primer GAGGGCAGTTGGTGTTTG
Forward primer CCACTCCTTCCTTATCTATCG
Eto2 intragenic Reverse primer GGGACAGGAGAAAGAAAGG
Forward primer TTCCACAGACACTCACTCTAT
Epb4.2 promoter Reverse primer AAGGAGGAAGCAGAAGGAC
Forward primer CCACGCTCTTTGGAGATGA
Epb4.2 3'UTR Reverse primer AGAACCTGACCGGCTACAGA
Forward primer AGACGGTTGAGGGTTGTTTG
Runx1+23enhancer Reverse primer CGAAAAATAAACCGGCAGTTGA
Forward primer CAAGCTGCCCACGTTATCAGT
Transcripts Sequence
RI1 Reverse primer TGCAGGCACTGAAGCACCA
Forward primer TCCAGTGTGAGCAGCTGAG
Gata1 Reverse primer TCCCAGTCCTTTCTTCTCTC
Forward primer TCCACAGTTCACACACTCTC
Eto2 Reverse primer CTTCACACCTCACACACAT
Forward primer CGTTCATCAAGAGACAGACC
Runx1 Reverse primer TAGCGAGATTCAACGACCT
Forward primer CTTGTGGCGGATTTGTAAAG
Epb4.2 Reverse primer TCCCAAACAACCCTCAACCGTC
Forward primer TGGTATGAAACATCTGAACACCCC
Myef2 Reverse primer CAGCGAACAGGAACATCA
Forward primer ATTGTGGAACCAAGTCTACC
Table S2. Primer sequence RT PCR used
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gene symbol chromosome logFoldChange
adjusted P
value
Mcpt4 14 -4.54366 0.000103
Mcpt2 14 -4.29734 0.000057
Erv3 2 -3.43546 0.000112
Tcrg-V2 13 -3.32504 0.000643
Nyx X -3.29649 0.000241
Lcp1 14 -3.01143 0.000107
Plxnc1 10 -2.89529 0.000031
Phlda2 7 -2.79519 0.000181
Lgals1 15 -2.58265 0.000057
Gzmb 14 -2.53060 0.000247
Slc18a2 19 -2.52303 0.000477
Vim 2 -2.50461 0.000103
Plac8 5 -2.39611 0.000112
Gsta4 9 -2.36564 0.000255
Dpp4 2 -2.35290 0.000107
Lgmn 12 -2.31035 0.000064
Slc45a3 1 -2.29088 0.000210
Fam198b 3 -2.28806 0.000191
Dazl 17 -2.24230 0.000723
Psen2 1 -2.21252 0.000240
Ass1 2 -2.18963 0.000250
Ifih1 2 -2.16847 0.000142
P2rx4 5 -2.15900 0.000107
Ephx2 14 -2.13600 0.001017
Rangrf 11 -2.12511 0.017121
Klhl6 16 -2.12191 0.000171
Arhgap15 2 -2.10519 0.000209
Gpr128 16 -2.10182 0.000262
Muc13 16 -2.07240 0.000584
BC035947 1 -2.05250 0.000275
Ifngr1 10 -2.01583 0.000240
Utp14a X -1.99767 0.000220
Eif3i 4 -1.98140 0.000191
Zadh2 18 -1.97941 0.000477
Myb 10 -1.97807 0.000103
Cmtm7 9 -1.92546 0.000173
Myo1d 11 -1.91515 0.000171
Fam129a 1 -1.89427 0.000589
Ccnb1ip1 14 -1.83198 0.001208
Gtf2h1 7 -1.81373 0.000171
Nudt19 7 -1.78905 0.000114
Txndc12 4 -1.78108 0.000103
Aldh3a1 11 -1.77922 0.000616
BC028528 3 -1.77688 0.000261
Mns1 9 -1.75885 0.001067
Fam158a 14 -1.75263 0.000171
Zfp637 6 -1.75186 0.000233
Fdx1 9 -1.69495 0.000484
Mcpt9 14 -1.68909 0.000107
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Lipa 19 -1.68625 0.000555
Hemt1 15 -1.68562 0.000854
Rpp40 13 -1.65247 0.001279
Tubb2b 13 -1.64779 0.000570
Ccbl2 3 -1.64663 0.000540
Jmjd1c 10 -1.61264 0.000672
Cpne3 4 -1.61186 0.000114
L2hgdh 12 -1.60232 0.000557
St6galnac3 3 -1.59210 0.000735
BC005685 4 -1.58498 0.002492
Mex3a 3 -1.57051 0.001354
Gm5662 12 -1.56312 0.012634
Acadsb 7 -1.55881 0.000503
4921507P07Rik 6 -1.55144 0.000301
Ivns1abp 1 -1.54356 0.000262
Ndst2 14 -1.54073 0.000388
Lhpp 7 -1.53947 0.000255
Xkr9 1 -1.53709 0.001341
Slc22a3 17 -1.53611 0.000181
Lypla1 1 -1.50653 0.000411
Ikzf2 1 -1.50374 0.000719
Hdc 2 -1.49928 0.002826
Intu 3 -1.49436 0.000240
Sep-06 X -1.48612 0.000366
Far2 6 -1.48357 0.005634
Sh3kbp1 X -1.48342 0.000727
Gm13023 4 -1.47913 0.000540
Ahcy 2 -1.47489 0.021071
St13 15 -1.47297 0.000255
Gna15 10 -1.47184 0.000240
Cd53 3 -1.47171 0.000327
Rnf125 18 -1.45930 0.000261
Gm8580 10 -1.44453 0.008802
Cdk6 5 -1.43467 0.000834
Dynlt3 X -1.41799 0.000171
Scpep1 11 -1.41587 0.000262
Mum1l1 X -1.41330 0.000668
Tgtp 11 -1.41018 0.003782
Fastkd1 2 -1.40967 0.001210
Ica1l 1 -1.39997 0.000672
Cpd 11 -1.38982 0.000247
Nfia 4 -1.38720 0.000638
H2afy 13 -1.38505 0.000240
Top1mt 15 -1.38209 0.000925
Slc4a11 2 -1.37950 0.001208
Tec 5 -1.37183 0.000698
Ptger4 15 -1.36960 0.000592
Aldh2 5 -1.36659 0.001445
Ogdhl 14 -1.36133 0.000756
Vps13c 9 -1.36108 0.000890
Rftn1 17 -1.36055 0.000857
Slc4a1 11 5.40952 0.000012
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Ppbp 5 4.84237 0.000012
Hbb-y 7 4.26905 0.000107
Aqp8 7 3.87234 0.000103
Acp5 9 3.85063 0.000057
Alas2 X 3.33518 0.000057
Csf2rb2 15 3.24487 0.000240
Epb4.2 2 3.10671 0.000057
Mybpc3 2 2.93576 0.000103
Fmo1 1 2.73506 0.000171
Gypa 8 2.69372 0.000114
Smox 2 2.59000 0.000107
Fam55b 9 2.56653 0.000103
Ephb2 4 2.52975 0.000194
Mgst3 1 2.51785 0.000254
Alad 4 2.51551 0.000103
Hemgn 4 2.49664 0.000112
Ahsp 2.47451 0.000107
Apol10a 15 2.46745 0.000967
Butr1 11 2.42574 0.000103
Tfrc 16 2.38377 0.000178
Glipr2 4 2.37402 0.000639
Fam110c 12 2.35880 0.000103
Plek2 12 2.33631 0.000553
Aim1 10 2.33278 0.000171
Dhrs11 11 2.33122 0.000103
Rab3il1 19 2.31303 0.000107
Itgb7 15 2.26140 0.000107
Itga2b 11 2.21809 0.000171
Gabrr1 4 2.18572 0.000499
Btg2 1 2.17810 0.000103
Tmem8 17 2.17298 0.000112
Rhd 4 2.15210 0.000314
F830116E18Rik 11 2.11057 0.000103
Dnajb2 1 2.09911 0.000255
Epb4.9 14 2.09649 0.000240
Grap2 15 2.07242 0.000201
Vangl1 3 2.02441 0.000103
Unkl 17 2.02396 0.000181
Hba-a2 11 2.01894 0.000103
Slamf1 1 1.98781 0.000141
Rph3al 11 1.98210 0.000107
Abcb10 8 1.98116 0.000137
Ube2l6 2 1.97777 0.000240
Lrrc39 3 1.93516 0.000114
Gm16494 17 1.92995 0.000309
E2f2 4 1.91889 0.000220
Hist1h2bc 13 1.90628 0.001435
Trim10 17 1.88604 0.000112
Slc30a10 1 1.88538 0.000112
Gm5226 17 1.88325 0.000366
Tmod1 4 1.88165 0.000141
1190002A17Rik 2 1.88134 0.000171
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Gpcpd1 2 1.87357 0.000107
Pdia2 17 1.86898 0.000854
Ank1 8 1.86609 0.000112
Arhgap23 11 1.85749 0.000103
Abcg2 6 1.85657 0.000114
Abcg4 9 1.85413 0.000107
Tmem86b 7 1.84906 0.000295
Arrdc3 13 1.83501 0.000327
Uros 7 1.83196 0.000255
Sema4b 7 1.82747 0.000347
Tbxas1 6 1.82627 0.000210
Slc6a9 4 1.82312 0.000191
2310046K01Rik 2 1.81926 0.000210
Pigq 17 1.81149 0.000114
Suv420h2 7 1.80867 0.000134
Josd2 7 1.80144 0.000262
Mylip 13 1.79264 0.000107
Mare 11 1.78912 0.000220
Slc43a1 2 1.77045 0.000112
Mageb16 X 1.74660 0.005780
4632428N05Rik 10 1.74261 0.000201
Gm6651 1 1.74190 0.001076
Fam132b 1 1.73687 0.000247
Hbb-b1 7 1.73282 0.002844
Micall2 5 1.72986 0.000692
Atp6v0a1 11 1.72186 0.000114
Ostb 9 1.71356 0.008197
Hmbs 9 1.70967 0.000211
Snca 6 1.70946 0.000361
1200009I06Rik 12 1.70152 0.001438
Appl2 10 1.68698 0.000114
Hmgn2 4 1.68331 0.000262
Il1r1 1 1.68097 0.000114
Cpeb4 11 1.67771 0.000215
Rrm2 12 1.67205 0.001089
Pkhd1l1 15 1.64859 0.001215
Ptdss2 7 1.64525 0.000181
Ccrl2 9 1.63923 0.001278
Capn5 7 1.63791 0.001292
Spns2 11 1.63635 0.001011
Hba-a1 11 1.63008 0.000171
Ampd3 7 1.62505 0.000262
Trp53inp1 4 1.61671 0.000112
Ptp4a3 15 1.61501 0.000233
Tlcd1 11 1.61429 0.000524
Cldn13 5 1.61357 0.000262
Slc6a3 13 1.61167 0.000112
Table S3 Top 100 up- and down regulated genes Runx1 KD non-induced MEL cells
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gene symbol chromosome logFoldChange
adjusted P
value
Gas5 1 -1.98301 0.016281
Rps25 9 -1.91058 0.033697
Eif3i 4 -1.87279 0.014645
Rps23 13 -1.83624 0.028973
Prepl 17 -1.77117 0.016281
Lypla1 1 -1.77093 0.016281
Hrsp12 15 -1.64764 0.022308
Ccdc104 11 -1.64512 0.020354
Tfb2m 1 -1.63433 0.023068
Acadsb 7 -1.55720 0.017310
Myb 10 -1.54417 0.027500
Snhg1 19 -1.54204 0.028973
Ranbp1 16 -1.54171 0.014645
Zdhhc2 8 -1.48375 0.016636
Ppia 11 -1.47632 0.017310
Lclat1 17 -1.46484 0.016636
Zfp120 2 -1.43627 0.016281
L2hgdh 12 -1.42852 0.016281
Thg1l 11 -1.42486 0.016281
Snora69 X -1.41979 0.022504
Wdr35 12 -1.40076 0.016281
Dynlt3 X -1.39749 0.017310
1700106N22Rik 17 -1.39601 0.029563
Eif2s2 2 -1.39017 0.017310
Nol8 13 -1.38737 0.043525
Gtf2h1 7 -1.38657 0.032245
Vkorc1 7 -1.38644 0.017310
Myc 15 -1.38418 0.022654
1110004F10Rik 7 -1.37133 0.016281
Nme2 11 -1.36668 0.017310
H2afy 13 -1.36426 0.016281
Tsr1 11 -1.35208 0.020354
Ccnb1ip1 14 -1.34342 0.028155
Slc38a1 15 -1.32545 0.024864
Snord58b 14 -1.32412 0.025108
Ktelc1 16 -1.32056 0.016281
Hspa13 16 -1.31962 0.037573
Uba6 5 -1.31856 0.016281
Echdc1 10 -1.31683 0.016281
Taf9b X -1.31594 0.024155
Tipin 9 -1.29866 0.016281
Rpp38 2 -1.29800 0.016688
Ttc26 6 -1.28315 0.017504
Etf1 18 -1.27638 0.016281
Mnd1 3 -1.27581 0.034089
2610524H06Rik 5 -1.27405 0.017310
Mtmr1 X -1.27385 0.017310
Dnajc10 2 -1.27359 0.016636
Iars 13 -1.26995 0.033791
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Tpr 1 -1.26458 0.018582
Dhx33 11 -1.26411 0.016281
Tmem48 4 -1.26291 0.016281
Lars 18 -1.25805 0.016281
Gpatch4 3 -1.25598 0.016281
Tmed5 5 -1.25536 0.023281
Rrp15 1 -1.25307 0.016281
Ppbp 5 3.13289 0.016281
Acp5 9 2.47846 0.012924
Aqp8 7 2.26321 0.016281
Csf2rb2 15 2.00402 0.034224
Mybpc3 2 1.99324 0.012924
Pkhd1l1 15 1.95249 0.057030
Speer4d 5 1.67309 0.022900
Rph3al 11 1.61124 0.048133
Cd59a 2 1.58084 0.026256
Mt2 8 1.55024 0.020874
Pfkp 13 1.54721 0.055885
Gm6560 5 1.51192 0.017310
Aldoc 11 1.48925 0.043525
Rogdi 16 1.46784 0.016281
Hba-x 11 1.38273 0.016281
Csf2rb 15 1.37419 0.052173
Prokr1 6 1.35853 0.023114
Cntn3 6 1.35306 0.016281
Ube2l6 2 1.34797 0.016281
Tcp11l2 10 1.31306 0.030923
Sly Y 1.28335 0.044876
Art4 6 1.28204 0.048186
2010011I20Rik 2 1.26355 0.023068
Ccng2 5 1.26220 0.042861
Man2b1 8 1.25007 0.016281
Table S4 All up and down regulated genes Runx1 KD induced MEL cells
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gene symbols chromosome logFoldChange
adjusted P
value
Slc4a1 11 -3,071385284 0,000320193
Apol10a 15 -2,76746958 0,001361583
Kdm1a 4 -2,598380651 0,000359823
Gm13646 13 -2,448156868 0,01543828
Epb4.2 2 -2,421292559 0,000337324
Cbx3 6 -2,340707079 0,006708892
Fam132b 1 -2,316888562 0,000654757
Hbb-b1 7 -2,260884131 0,001564986
Rhag 17 -2,174250988 0,001018278
Cldn13 5 -1,791683742 0,001490332
Atp11c X -1,740076499 0,002717412
Rhd 4 -1,738413174 0,001490332
Ptges3 10 -1,707186342 0,002591066
Mageb16 X -1,706987419 0,02363356
Cstf3 2 -1,649006653 0,006942271
Grsf1 5 -1,646208427 0,001564986
Abcb4 5 -1,605701172 0,001490332
Slc25a37 14 -1,59396606 0,002608395
Gp5 16 -1,586127892 0,007754596
Butr1 11 -1,560957695 0,002717412
Tmem56 3 -1,558833963 0,002553892
Ppia 11 -1,551112346 0,01109665
Trim10 17 -1,486077347 0,002751119
Slc7a11 3 -1,479915882 0,002553892
Ndufa4l2 10 -1,471813907 0,002553892
Cbr1 16 -1,466193756 0,006942271
Kcnn4 7 -1,450955808 0,001534655
Mgst3 1 -1,449082746 0,00266996
Tmem59 4 -1,440820716 0,002553892
Gm16494 17 -1,427717905 0,00293519
Kel 6 -1,426307026 0,00266996
Rps23 13 -1,400163393 0,022951837
Aldh1a1 19 -1,378854133 0,001564986
Slc22a4 11 -1,372145205 0,004129658
Rpl15 14 -1,370357905 0,025123647
100043387 2 -1,362770259 0,024577727
Unkl 17 -1,358645396 0,001597451
Mif 10 -1,355021083 0,018113779
Hmgb1 5 -1,353180082 0,00629465
2610002M06Rik X -1,352038265 0,003169919
Trim2 3 -1,348298873 0,003488361
Hemgn 4 -1,317432641 0,001564986
Abcg2 6 -1,314953293 0,001564986
Taok1 11 -1,310373366 0,007639919
Hist1h2an 13 -1,307049468 0,006185187
Arhgdig 17 -1,30005765 0,003224985
Lrrc39 3 -1,293032002 0,004142438
Tfrc 16 -1,279955231 0,002591066
Gbp6 3 -1,259795254 0,002553892
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Ralgapa1 12 -1,258556619 0,001953449
Atf5 7 -1,252651069 0,002256776
Slc1a4 11 -1,25131079 0,003586649
Lgals1 15 3,122148997 0,000182282
Lgmn 12 2,775683482 0,000337324
Hemt1 15 2,651913263 0,002591066
Cd53 3 2,596621368 0,001534655
Rogdi 16 2,55575549 0,001564986
Tmem173 18 2,364107669 0,000337324
Spna2 2 2,293372372 0,000601245
Vim 2 2,151154018 0,000952682
Mcpt2 14 2,046652533 0,001271512
Mcpt4 14 1,985344267 0,000683854
Hmox1 8 1,89357069 0,001509079
5530401N12Rik 17 1,88679884 0,004110834
BC028528 3 1,867500409 0,000906269
Fmo1 1 1,861758213 0,000906269
Srsy Y 1,840141266 0,034427865
F2r 13 1,794914899 0,001490332
Ahsg 16 1,773199588 0,002553892
Gm8995 7 1,727061829 0,004129658
Neurl3 1 1,69408237 0,00293519
Meis1 11 1,685913396 0,002553892
1700025G04Rik 1 1,656045354 0,002717412
Pld4 12 1,641867589 0,001057325
Rel 11 1,6332725 0,001490332
Lcp1 14 1,620450797 0,002553892
Snord116 7 1,599535673 0,008622841
Muc13 16 1,578501563 0,002553892
Arhgdib 6 1,563847073 0,002591066
Sgpl1 10 1,561484616 0,001351164
Scpep1 11 1,548985133 0,001490332
Syne2 12 1,541229637 0,001564986
Cep55 19 1,506144886 0,001351164
F2rl2 13 1,493165206 0,003380506
Lpin2 17 1,480049737 0,001564986
Map3k3 11 1,455578567 0,002717412
Appl2 10 1,43821225 0,003285437
Pls3 X 1,433348452 0,003255274
Plxna3 X 1,425773796 0,002591066
Ehd3 17 1,413546794 0,001490332
Nrgn 9 1,372240569 0,001564986
Tmem50b 16 1,369507309 0,001953449
Elmo1 13 1,351166108 0,00266996
Plp2 X 1,315625563 0,002928708
S100a6 3 1,307663168 0,002412225
Tnfaip8 18 1,301414621 0,002717412
Cd7 11 1,298444157 0,003009361
Vat1 11 1,289627766 0,011834943
1500035H01Rik 9 1,287397674 0,002735748
Lamb2 9 1,280845868 0,004142438
Tnfaip1 11 1,280452917 0,004653312
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Plac8 5 1,278718234 0,002591066
Schip1 3 1,271496084 0,006837863
Egfl7 2 1,266266586 0,002591066
Klhl6 16 1,265073595 0,004142438
Ifngr2 16 1,253443738 0,002591066
Table S5 All up and down regulated genes LSD1 KD induced MEL cells
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S6. LSD1 immunoprecipitation. Antibody IP of endogenous LSD1 in non-induced 
and induced MEL cells. Control IP normal Rabbit serum. Western blot stained for 
LSD1 and Runx1.
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S7. Bio-V5-Runx1 immunoprecipitation. V5 IP of Bio-V5-Runx1 in non-induced 
and induced MEL cells. V5 IP in MEL cells used as control. Western blot stained for 
Runx1 and Myef2
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S8. Runx1 and Bio-V5-Runx1 binding to +23 enhancer runx1 locus. Runx1 antibody 
ChIP and V5 ChIP of Bio-V5-Runx1 in non-induced MEL cells. Control normal Rabbit 
IgG and V5 ChIP in MEL cells.
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Summary
Erythropoiesis is the generation of erythrocytes from the haematopoietic stem cell 
(HSC). This process is regulated by transcription factor complexes that change as 
erythropoiesis progresses. Our lab uses the Mouse Erythro-Leukaemia (MEL) cell 
line as a model system for terminal erythroid differentiation to identify transcription 
factors involved in this process. MEL cells overexpress the transcription factor Pu.1, 
which is an antagonist of Gata1 and halts differentiation at the proerythroblast stage 
but they can be chemically induced to differentiate towards terminal erythrocytes. 
A complex was identified in erythroid cells that is important for erythropoiesis and 
contains important erythroid transcription factors like Gata1, LDB1, Tal1 and Eto2. 
The transcription factor Runx1 was also identified as part of this complex while it was 
unknown to have a role in erythropoiesis. To investigate the potential role of Runx1 
in erythropoiesis a Bio-V5 tagged version of Runx1 was expressed in MEL cells to 
first identify its protein partners using immunoprecipitations and mass spectrometry 
analysis. This yielded a number of proteins that were previously described as part 
of the complex but also new partners. Two novel factors were also identified to 
form a complex with Runx1, Myef2 in the proerythroblast stage of erythropoiesis 
and LSD1 later in erythropoiesis. Next the genome wide Runx1 DNA binding sites 
were determined in the proerythroblast and later stages of erythroid development 
using ChIP-sequencing. In a genome-wide analysis comparing Runx1 binding sites 
with differentially expressed genes from proerythroblast to erythrocyte differentiation 
showed that Runx1 binds erythroid specific genes during erythroid development. 
Binding to the important erythroid genes gata1, eto2 and epb4.2 was confirmed. 
Further more it was shown that the DNA binding sequences of Gata1 and Tal1 were 
overrepresented near Runx1 binding sites suggesting that cooperation of these 
transcription factors is important for erythroid development. 
When a genome-wide expression analysis of Runx1 depleted MEL cells showed that 
Runx1 functions as an activator and repressor at the proerythroblast stage. When the 
cells differentiate towards erythrocytes much fewer genes are regulated by Runx1 
although its genome-wide binding pattern does not change much. The expression 
levels of the genes gata1, eto2 and epb4.2 were measured independently after 
Runx1 knock-down which showed that these are indeed upregulated. Thus Runx1 
functions as a repressor of these genes in the proerythroblast stage. A knock-down 
of Myef2 also showed an upregulation of the transcription of these three genes, 
suggesting that Runx1 forms a complex with Myef2 in the proerythroblast stage to 
represses a group of erythroid genes. After the proerythroblast stage this complex 
disassociates and repression is lifted although Runx1 stays bound to these genes. 
This role of Myef2 was unknown in erythropoiesis and we confirmed its function by 
zebrafish oligonucleotide morpholino injections against Myef2 mRNA. This confirmed 
a role for Myef2 in erythropoiesis but also showed an effect on T-cell development 
and HSC development probably mediated via Runx1.
After the proerythroblast stage Runx1 still regulates a number of genes while it forms 
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a complex with LSD1. LSD1 is and histone demethylase and represses genes by 
removing the activating mark on histone 3 lysine 4 (H3K4) mono and di-metylation. 
When LSD1 is recruited to genes repressed by Runx1 in differentiating cells the 
H3K4 mono- and di-methyl mark is partially removed. This suggests that Runx1 
represses genes during terminal erythropoiesis by recruiting LSD1 to these genes 
after the proerythroblast stage. Runx1 also activates genes during erythropoiesis 
but it is unclear from our data how this function is mediated. 
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Samenvatting
Erytropoiese is de differentiatie van de hematopoietische stamcel (HSC) naar 
rode bloedcel (erytrocyt). Dit proces wordt gereguleerd door complexen van 
transcriptiefactoren die van samenstelling veranderen tijdens de erytropoiese. 
Tijdens het onderzoek is gebruik gemaakt van de Mouse Erythro-Leukaemia (MEL) 
cellijn, die model staat voor terminale erytropoiese, om transcriptie factoren te 
identificeren die bij dit proces betrokken zijn. MEL cellen brengen de transcriptiefactor 
Pu.1 tot overexpressie die een antagonist is van Gata1 en stopt de differentiatie 
in de pro-erytroblast fase. Door toevoegingen van bepaalde chemische stoffen kan 
differentiatie worden geïnduceerd in de richting van terminale erythropoiese.
In erytroide cellen was een eiwit complex geïdentificeerd die belangrijk is voor de 
erytropoiese en bevat belangrijke erythroide transcriptiefactoren zoals Gata1, 
LDB1, Tal1 en Eto2. De transcriptiefactor Runx1 was ook geïdentificeerd als 
een deel van dit complex terwijl een rol in erytropoiese onbekend was. Om deze 
potentiële rol in erytropoiese te onderzoeken werd er een Bio-V5 gelabelde versie 
van Runx1 geëxpresseerd in MEL cellen om eerst zijn eiwit partners te identificeren 
via immunoprecipitatie en massa spectrometrie. In deze analyse werden eiwitten 
geïdentificeerd waarvan bekend was dat ze onderdeel uitmaakten van het complex. 
Ook werden twee nieuwe eiwitten ontdekt die in een complex zitten met Runx1. 
Dit waren Myef2 in de pro-erytroblast stadium en LSD1 in latere erytropoiese. 
Hierna werden alle genomische bindingsplaatsen van Runx1 bepaald in de pro-
erytroblast en latere stadia van de erytroïde ontwikkeling via ChIP-sequencing. In 
een vergelijking tussen alle genomische Runx1 bindingsplaatsen en differentieel 
geëxpreseerde genen van de pro-erytroblast naar erytrocyten vinden we dat Runx1 
aan erytroïde specifieke genen bindt. De binding aan belangrijke erytroïden genen 
zoals gata1, eto2 en epb4.2 werd bevestigd. 
Wanneer dezelfde analyse werd gedaan maar nu met MEL cellen met een 
verminderd Runx1 expressie vinden we dat Runx1 zowel als een activator als een 
repressor functioneert tijdens de pro-erytroblast stadium. Na differentiatie vinden we 
dat er veel minder genen door Runx1 gereguleerd worden, maar de totale binding 
aan het genoom veranderd niet veel. De expressie van gata1, eto2 en epb4.2 is 
verhoogd in MEL cellen met een verminderde Runx1 expressie. Hieruit bleek dat 
Runx1 functioneert als een repressor van deze genen in de pro-erytroblast stadium. 
Ook in MEL cellen met een verminderde expressie van Myef2 zijn deze drie genen 
opgereguleerd, wat suggereert dat Runx1 een complex vormt met Myef2 in het pro-
erytroblast stadium en een groep erytroïde genen represeert. Deze rol van Myef2 
in erytropoiese was onbekend en werd bevestigd door zebravis oligonucleotide 
morpholino injecties tegen het mRNA van Myef2. Dit bevestigde de rol van Myef2 
in erytropoiese. Verder werd een effect gezien in T-cel en HSC ontwikkeling 
waarschijnlijk gemedieerd via Runx1.
Na het pro-erytroblast stadium reguleert Runx1 nog steeds een aantal genen en 
vormt een complex met LSD1. LSD1 is een histon demethylase en represeert genen 
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door het verwijderen van de activerende markering op histon 3 lysine 4 (H3K4) mono- 
en di-methylatie. LSD1 wordt gerekruteerd naar genen door Runx1. Deze genen 
worden gerepreseerd tijdens differentiatie door Runx1. Waarschijnlijk word door 
de rekrutering van LSD1 de H3K4 mono en di-methylatie gedeeltelijk verwijderd. 
Dit suggereert dat Runx1 genen represeert tijdens terminale erythropoiese door 
het rekruteren van LSD1 naar deze genen na het pro-erytroblast stadium. Runx1 
activeert ook genen tijdens de erytropoiese maar hoe dit werkt blijkt niet uit onze 
data.
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